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Tumor environment influences the response to anti-cancer therapy, but which
extracellular nutrients impact drug sensitivity is largely unknown. In this work, we used
functional genomics to identify metabolic modifiers of the response to L-asparaginase
(ASNase), a therapy that depletes plasma asparagine and targets leukemic cells with
insufficient asparagine synthesis.
Our approach revealed thiamine pyrophosphate kinase 1 (TPK1), which converts
vitamin B1 (thiamine) into the cofactor thiamine pyrophosphate (TPP), as a metabolic
dependency under ASNase treatment. In glutamine-anaplerotic leukemia cells, we
found that TPP availability enables asparagine synthesis from extracellular glutamine.
Mechanistically, TPP is critical for the activity of alpha-ketoglutarate dehydrogenase
(AKGDH), a TCA cycle enzyme that catalyzes a step in the overall conversion of
glutamine to asparagine. When TPP availability is limiting for cell proliferation of TPK1
KOs, ASNase sensitivity is significantly increased.
Standard cell culture media formulations provide thiamine at a concentration that
is ~100-fold higher than that observed in human plasma. While thiamine is generally not
limiting for cell proliferation under standard culture conditions, a DNA-barcode
competition assay identified a subset of leukemia cell lines that grow sub-optimally
under lower, more physiological thiamine levels. These cell lines are characterized by
low expression of SLC19A2, a high affinity thiamine transporter. Intriguingly, SLC19A2
expression was necessary for not only optimal growth, but also for maintaining ASNase
resistance, when standard media thiamine was lowered to the concentration of human
plasma.
Importantly, analyzing RNAseq data of pediatric acute lymphoblastic leukemia
(ALL) tumor samples revealed that SLC19A2 is the primary thiamine transporter
expressed in these cancers, and that SLC19A2-low tumors exist among patients. To
model such tumors, we used a SLC19A2-low cell line to generate orthotopic tumors in
NSG mice. Remarkably, humanizing blood thiamine content of mice through diet
sensitized these leukemia cells to ASNase in vivo.
Altogether, our work reveals that utilization of thiamine is a determinant of
ASNase response for some cancer cells, and that over-supplying vitamins may impact
therapeutic response in leukemia. Additionally, our work adds to the recent literature
that demonstrates how physiological levels of certain nutrients in cell culture can affect
therapy. Specifically, our work provides the first proof of principle that humanizing the
vitamin levels of both in vitro and in vivo models can affect drug sensitivity. This has
broad implications for the screening and validation of new therapeutic candidates.

To my parents, my sister, Jill, and Olive
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CHAPTER 1. Introduction

1.1 Nutrient availability influences cellular metabolism and therapeutic response
Nutrient availability in the tumor environment influences the metabolism of cancer cells,
and may result in dependencies that can be exploited for therapy (1, 2). Indeed,
deprivation of highly consumed extracellular nutrients in tumors may impose cancer
cells to use specific metabolic pathways for proliferation and survival. For instance, low
tumor glucose concentrations upregulate oxidative phosphorylation, an essential
adaptation that can be targeted by the biguanide class of drugs (3). Similarly,
environmental pyruvate and glutamine levels may determine the anaplerotic substrate
cancer cells rely on (4). Interestingly, exogenous modulation of tumor nutrient supply
can also affect metabolic programs, and consequently, therapeutic response (5).
Through effects on one-carbon metabolism, histidine supplementation or dietary
methionine restriction sensitizes cancer cells to commonly used chemotherapeutic
agents (6, 7). The use of physiological cell culture media has further demonstrated that
nutrient environment induces metabolic changes that affect drug sensitivity (8). In these
recent studies, simply bringing media concentrations of uric acid and cystine to
physiological levels altered cancer cell responses to 5-fluorouracil and CB-839,
respectively (9, 10). Taken together, these examples illustrate the need for further
investigation into which nutrients impact therapeutically-relevant metabolic pathways. In
particular, it is poorly understood whether vitamins, which act as cofactors for many
metabolic reactions, can affect responses to anti-cancer drugs.
1.2 Specific vitamin dependencies in cancer and how they can be targeted
Cancer cells may demonstrate increased dependencies on vitamins due to their need
for particular vitamin-dependent reactions or because of defects in vitamin transport or
activation. Vitamin B9, or folate, is a precursor for tetrahydrofolate, a coenzyme involved
in enzymatic transfer of one-carbon groups in various amino acid and nucleic acid
synthesis pathways collectively referred to as one-carbon metabolism. As many cancers
rely on one-carbon pathways for proliferation (11), targeting one-carbon metabolism
pathways with drugs such as methotrexate and 5-fluorouracile (5-FU) has been a
successful strategy since the 1940s (12).
Few reports have identified vitamin utilization defects such as impaired transport or
inability to synthesize activated derivatives, defects that can be exploited
therapeutically. In breast cancer cells, thiamine transporters (SLC19A2 and SLC19A3)
have been found to be expressed at lower levels than their normal tissue counterparts.
This led to the hypothesis that decreased thiamine transporter expression may make
these cancers more dependent on exogenous thiamine, a vulnerability that can be
targeted with acute thiamine starvation (13, 14). To circumvent the effects of chronic
thiamine starvation, studies utilized a recombinant thiaminase enzyme that digests
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thiamine and induces an acute thiamine depletion state (15). One subset of leukemias
were more dependent on extracellular thiamine than other tested cell lines (15, 16). In
follow-up studies, thiaminase was found to have in vivo efficacy against breast cancer
and leukemia subcutaneous xenografts, as well as primary ALL cells injected
intravenously (17). These thiaminase studies provide interesting examples of differential
dependencies on extracellular vitamin levels possibly explained by varying degrees of
vitamin transport capabilities.
Another vitamin with reported heterogeneity in transporter expression across normal
and cancerous tissues is riboflavin. Some riboflavin transporters were observed to be
overexpressed in melanoma, breast cancer, and squamous cell carcinoma samples
relative to healthy tissues (18). While these expression patterns may be useful for
designing targeted drug-delivery systems, these findings may suggest the existence of
cancers with increased riboflavin dependencies. It is also possible for cancers to have
vulnerabilities in vitamin utilization downstream of extracellular uptake, such as in the
enzymatic conversion of vitamins to activated derivatives. Examples include vitamin B6,
an umbrella term for the 6 different vitamers that require different enzymatic steps for
interconversion before yielding the activated cofactor form, pyridoxal phosphate (PLP)
(19). Dependencies on exogenous pyridoxal (PL) or PLP forms of vitamin B6 have been
observed in some tumors (20). Overall, with the exception of folate, there are promising
but few reports on unique vitamin dependencies in cancer. Studying these
dependencies could lead to dietary interventions or new therapeutic targets that could
be as impactful as anti-folates have been for the last several decades.
1.3 Acute lymphoblastic leukemia (ALL)
1.3.1 Biology and pathophysiology
Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells (WBCs), primarily
arising from cells of the B and T lineages. B-cell ALL represents ~85% of childhood and
~75% of adult ALL cases, and T-cell ALL makes up the majority of the remaining cases
in both age groups (21, 22). As a hematologic malignancy, the disease affects blood
and lymph nodes, as well as bone marrow, where WBCs are originally produced. The
most common presenting symptoms reflect these disease sites, and include blood
abnormalities such as anemia and bleeding, lymph node involvement appearing as
lymphadenopathy or hepatosplenomegaly, and bone pain due to marrow colonization
(23). Since the involvement of both blood and lymphoid organs can result from the
same initial white blood cell cancer, recent classification guidelines recognize these
leukemias and lymphomas as a single disease that may also be referred to as acute
lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). For simplicity, the
remainder of this thesis will use the more established and widespread term “ALL”.
The majority of ALL cases arise spontaneously with no known cause, but some
environmental and genetic factors have been associated with an increased risk of ALL
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occurrence (22, 24). Exposure to ionizing radiation has been linked with ALL, but most
studies that examine the influence of environmental factors on ALL incidence have
yielded inconsistent results (25). Among genetic syndromes, Down’s Syndrome is most
commonly associated with increased risk of ALL (24, 26). Additionally, germline
mutations in ETV6, PAX5, and TP53 have been associated with rare familial ALL cases
(27-32). Finally, genome-wide association studies have implicated multiple genes as
having polymorphic variants that increase the risk of ALL, including ARID5B, CEBPE,
and IKZF1, which are annotated as genes involved in B-cell progenitor transcriptional
regulation and differentiation (33, 34). Some of these factors that increase ALL risk have
prognostic and therapeutic significance. For instance, TP53 mutations and IKZF1
alterations are notable for their associations with ALL subtypes that have poor
outcomes, and patients with abnormalities in these genes are assigned to high-risk
chemotherapy regimens (21, 24).
In addition to the genetic factors that predispose individuals to ALL, there are many
common genomic alterations that arise spontaneously during leukemic cell
transformation. These alterations are also important for prognosis and are used for risk
stratification and assigning therapy (21, 22). Among the most common cytogenetic
changes are ETV6-RUNX1 rearrangements and hyperdiploidy, which each carries a
favorable prognosis (21, 35, 36). In contrast, less common genomic features may be
associated with poor prognosis, leading to augmented chemotherapy protocols, or
targeted treatment if applicable. In patients with previously high-risk Philadelphia
Chromosome-positive ALL (Ph-positive ALL), targeting BCR-ABL1 with the ABL-class
tyrosine kinase inhibitor (TKI) imatinib led to improved outcomes (37-41). Additionally, a
high-risk ALL subtype termed Ph-like ALL does not express BCR-ABL1 but does
contain kinase-activating genomic rearrangements involving genes like ABL1, JAK2,
and PDGFRB, and may benefit from ABL-class TKIs like imatinib as well as JAK
inhibitors like ruxolitinib (42-48). Recently, the FLT3 overexpression observed in highrisk ALL with rearranged KMT2A (also referred to as MLL) has been targeted with FLT3
inhibitors, in preclinical and clinical settings (49-51). Of note, the use of targeted
therapies in ALL is still in early stages, and the vast improvements in ALL outcomes in
the last few decades are largely attributed to the fine-tuning of treatment regimens
involving established chemotherapeutics (24). However, the positive clinical outcomes
observed with targeted therapies thus far demonstrate the need for further investigation
of whether ALLs of certain genotypes may benefit from specific medications.
1.3.2 Epidemiology and outcomes
ALL is the most common cancer in children, representing ~26% of new cancer
diagnoses in patients of ages 0-14 (52). In the United States, this translates to ~3,000
new childhood ALL cases every year (21, 24). Fortunately, survival rates for childhood
ALL have increased steadily over the last few decades (24, 53, 54), and five-year
overall survival for childhood ALL is currently ~90% (24, 55). However, there are also
~3,000 adult ALL cases diagnosed annually in the United States, and adult ALL patients
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are generally considered to be high risk cases with a worse prognosis (22, 24, 56). This
is reflected in the 5-year overall survival for adult ALL, which has improved in the last
decades but is still estimated to be ~40%, with lower survival rates observed in older
populations (57-60).
The increase in 5-year survival for childhood ALL over the years has been attributed to
the introduction of multi-drug, multi-phase regimens in the 1960s and 1970s (61-63), the
inclusion of treatments aimed at preventing relapse within the central nervous system
(CNS) (64), and the continuous improvement of risk stratification practices used to place
patients on appropriate regimens (24, 63). Furthermore, the recent improvements in
outcomes for adult ALL patients are associated with adapting successful pediatric
protocols for use in adult patients (65-67). Although pediatric treatment regimens have
proven effective in both children and adults, the survival rates for both childhood and
adult ALL demonstrate that a significant number of patients in both age groups still fail
these treatment protocols today. Thus, there is a need for continued research into not
only new drug candidates, but also the improvement of existing ALL treatment protocols
however possible.
1.3.3 Risk stratification and treatment
Although many factors have been evaluated for their importance in predicting ALL
outcomes over the last few decades, only five are still routinely used for risk
stratification: age, initial WBC count, leukemic cell cytogenetics and ploidy, immunologic
subtype (B or T lineage), and initial treatment response (24, 63). Increased age, higher
WBC count, certain cytogenetic features such as a BCR-ABL1 fusion, T-cell ALL, and
persistence of disease after the first treatment phase are all indicators of a high-risk
case (24). If a patient has high-risk characteristics, then standard multi-phase
chemotherapy regimens may be augmented in terms of dose and frequency, or with
additional medications (68, 69). Additionally, targeted treatments may be added for
patients with specific cytogenetic characteristics. As stated above, patients with a BCRABL1 fusion have a survival benefit with addition of the tyrosine kinase inhibitor (TKI)
imatinib to standard therapy (39-41, 70), and to circumvent resistance or poor CNS
penetration with imatinib, second- and third-generation TKIs have also been used with
positive outcomes (71-77). Specific treatments have also been used recently for each
immunologic subtype in refractory and relapsed cases. Blinatumomab is an antibody
therapy that has produced survival benefits in advanced B-ALL (78-81), and nelarabine
is a T-cell specific chemotherapy that has had success in refractory and relapsed T-ALL
patients (82). However, allogeneic stem cell transplantation remains the gold standard
for all refractory and relapsed ALL cases (22), and is beneficial for high-risk patients
after completion of the initial phase of chemotherapy (83-86).
Current treatment for standard-risk ALL patients involves multi-drug chemotherapy
regimens, given as five phases of treatment that each last at least 1 month: induction,
consolidation, interim maintenance, delayed intensification, and maintenance (24, 68).
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Many of the medications and drug classes used in the initial induction and consolidation
phases are used again in later phases, with possible substitution of certain drugs for
another of the same class to further help eliminate residual drug-resistant cancer cells
(Table 1). In standard pediatric regimens, the induction phase includes the
chemotherapeutic vincristine, a corticosteroid such as prednisone, and the metabolismfocused drug asparaginase (ASNase). In most cases, the induction phase causes a
complete remission, but additional treatment phases are needed to prevent relapse
(24). In the next treatment phase, consolidation, patients receive multiple
chemotherapeutics that act by causing DNA damage or preventing DNA synthesis in
proliferating cells (Table 1). Additionally, throughout these first two treatment phases
and some of the subsequent phases, chemotherapies targeting DNA synthesis are
administered directly into the spinal canal (24, 68). This is to prevent relapse of
leukemia within the CNS, which would previously occur in the majority of patients who
achieved complete remission with systemic chemotherapy (24, 64).

Table 1.1. Components of standard ALL treatment.
Drug

Type

Target

cyclophosphamide

chemotherapy

DNA stability

daunorubicin

chemotherapy

DNA stability

doxorubicin

chemotherapy

DNA stability

cytarabine

chemotherapy

DNA synthesis

6-mercaptopurine

chemotherapy

DNA synthesis

6-thioguanine

chemotherapy

DNA synthesis

vincristine

chemotherapy

microtubule formation

dexamethasone

steroid

various signaling pathways in WBCs

prednisone

steroid

various signaling pathways in WBCs

methotrexate

DHFR inhibitor

one-carbon metabolism

L-asparaginase

enzyme

asparagine availability

Overall, the medications used in the various treatment phases of ALL are drugs that
non-specifically target processes common to all proliferating cells, such as DNA
synthesis. Interestingly, two of the therapies used in standard ALL treatment act by
limiting the cellular availability of important metabolites. Methotrexate is a drug of the
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antifolates class that inhibits dihydrofolate reductase (DHFR), the enzyme required for
converting folate (vitamin B9) into tetrahydrofolate (THF), a folate derivative that is
essential for DNA synthesis and other cellular processes (11, 12). L-asparaginase
functions by depleting circulating levels of the amino acid asparagine, which forces
leukemia cells to obtain sufficient intracellular asparagine for proliferation via
mechanisms other than uptake (87, 88). Interestingly, the nutrient environment has
been shown to influence leukemic cell responses to both methotrexate and ASNase.
1.3.4 Nutrient supplements affect components of ALL therapy
Folic acid, a synthetic conjugate base of folate, is readily available as a dietary
supplement (89). For decades, some clinicians have advised against folic acid
supplementation during methotrexate treatment of ALL (89-91). This advice stems from
several observations. First, in the 1940s, Sidney Farber and his colleagues reported
that administration of folic acid conjugates accelerates pediatric leukemia (92). This
observation led to the seminal study that demonstrated the antifolate aminopterin (later
replaced by methotrexate) could cause temporary remission of childhood leukemias
(93). In addition to its growth-promoting effect in leukemia, supplemental folate has also
been shown to interfere with leukemic cell uptake of methotrexate (94, 95). Finally,
folate competes with methotrexate for the enzyme folypolyglutamate synthase that is
required to produce polyglutamylated derivatives of these compounds, and
polyglutamylated methotrexate has greater intracellular retention than methotrexate and
contributes significantly to cytotoxicity (90, 91, 96).
In cells, folate is metabolized into various derivatives, including folinic acid (5-formylTHF), a compound that is available as both a commercial vitamin supplement and as
the chemoprotective medication leucovorin (90). Although folic acid supplements are
not recommended during methotrexate treatment, folinic acid is used in the form of
leucovorin to rescue toxicity in normal tissues by administration at adequate time-points
following methotrexate treatment (90). Folinic acid is formed downstream from the
DHFR reaction inhibited by methotrexate, and can be converted to THF for use in
cellular metabolic reactions (89, 97). Thus, in multiple mouse and cell culture studies,
folinic acid reversed the anti-cancer effects of methotrexate when administered
simultaneously (90). As folinic acid is readily available as a nutritional supplement,
patients must be advised against taking these supplements without clinician oversight,
as dosage and timing may affect methotrexate treatment (90).
Recently, exogenous supplementation of the amino acid histidine was shown to
increase methotrexate sensitivity of leukemic cancer cell lines in vivo (6). Histidine
catabolism utilizes THF, and increasing the flux of histidine into this degradation
pathway depletes the cellular THF pools that are already in limited supply during DHFR
blockade by methotrexate (6). Thus, along with folic acid and folinic acid, histidine is
now one of the known readily-available nutritional supplements that can influence
methotrexate response of leukemia cells.
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Of the other medications used in standard ALL treatment, ASNase stands out as
another therapy whose efficacy can be influenced by environmental nutrient availability
(98, 99). However, exactly which extracellular metabolites affect ASNase sensitivity
remains poorly understood.
1.4 Leukemic cell response to L-Asparaginase (ASNase)
L-asparaginase (ASNase) is a first-line chemotherapeutic for acute lymphoblastic
leukemia (ALL) that depletes the amino acid asparagine from blood, thereby targeting
leukemia cells that are unable to synthesize sufficient asparagine (87, 88). ASNase is
unique among ALL therapies in that it exploits a specific metabolic vulnerability,
observed several decades ago. The history of ASNase in cancer treatment dates back
to the 1950s, when John Kidd first discovered that administering guinea pig serum to
mice harboring transplanted lymphomas, or rats harboring transplanted
lymphosarcomas, caused the cancers to regress (100, 101). In the early 1960s, J.D.
Broome brought to light the observation that L-asparaginase is abundant in serum of
guinea pigs but not other mammals, a phenomenon that had first been reported in the
1920s (102, 103). In a series of experiments, Broome then demonstrated that the Lasparaginase component of guinea pig serum was indeed responsible for its therapeutic
effect (102, 103). ASNase was subsequently purified from E. coli and used in multiple
clinical studies beginning in the late 1960s, in which it successfully treated ALL even as
a monotherapy (104-107). Today, ASNase is a component of standard multi-agent
treatment protocols for ALL. Unfortunately, as reflected in the current outcomes for
childhood and adult ALL, not all patients respond to contemporary ASNase-containing
regimens. Furthermore, the determinants of ASNase response in ALL remain
incompletely understood.
Major determinants of ASNase sensitivity include basal expression of asparagine
synthetase (ASNS), a key enzyme that converts aspartate to asparagine, as well as the
capacity to upregulate ASNS through ZBTB1 and activating transcription factor 4
(ATF4) (108, 109). Recent work has identified alternative ways of increasing asparagine
availability, such as through proteasome degradation (110) or aspartate uptake by
solute carrier family 1 member 3 (SLC1A3) (111). Additionally, other cell types can
secrete asparagine or its precursors, which ALLs can utilize, attenuating ASNase
cytotoxicity (98, 99). These latter studies are particularly interesting because they
exemplify that environmental nutrient availability can affect ASNase response of ALL
cells. It remains unclear, however, whether extracellular nutrients that are not
asparagine precursors can influence sensitivity to ASNase.
1.5 Overview and Significance of findings
Using a CRISPR/Cas9-based genetic screen, here, we interrogated the metabolic
determinants of ASNase sensitivity in leukemia. Our analysis pinpointed thiamine
pyrophosphate kinase 1 (TPK1) as essential for proliferation under ASNase treatment.
7

TPK1 converts thiamine to thiamine pyrophosphate (TPP), a cofactor necessary for the
activity of the alpha-ketoglutarate dehydrogenase (AKGDH) complex. In glutamineanaplerotic leukemia cells, TPP availability enables asparagine synthesis from
extracellular glutamine, when asparagine is depleted. We further identified that
physiological levels of thiamine do not limit cell proliferation or ASNase resistance in
most cancer cell lines, except for those that have low expression of SLC19A2, a
thiamine transporter. These cancer cell lines become sensitive to ASNase when
thiamine concentration is lowered to human plasma levels, which is ~100-fold lower
than standard culture conditions. Consistent with this observation, a diet that humanizes
mouse plasma thiamine levels sensitized leukemia xenografts with endogenously-low
SLC19A2 to ASNase. Altogether, our results suggest that SLC19A2 expression may be
a determinant of ASNase response and that supra-physiological thiamine
supplementation could potentially ablate such an association. Furthermore, our work
provides a proof of concept that using human physiological vitamin levels can affect
cancer cell sensitivity to therapies.
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CHAPTER 2. Metabolic determinants of proliferation under ASNase treatment

2.1 In vivo ASNase responses of 62 cancer cell lines using a barcode-based
competition assay
To simultaneously test the responses of several cell lines to ASNase treatment, I first
worked on expanding a previously reported barcoded cell line library that allows for cell
competition assays under nutrient deprivation conditions (3). By inserting one or more
permanent DNA barcodes into a cell line, the response of that cell line can be tracked
through an experiment in which a pool of barcoded cell lines are grown together in a
single vessel. By comparing responses in a vessel with replete medium to responses in
a vessel containing a single nutrient depletion, we can screen for cell lines that may be
resistant or sensitive to that particular nutrient depletion. These results can then be
validated using individual cell line proliferation assays. This technique was first used to
test responses of 28 cell lines to low glucose (3). Since the initial publication of this
technique, our lab has continued to barcode cell lines, and we now have over 60 cell
lines that can be included in a single competition experiment.
Our expanded library of barcoded cell lines is largely composed of diverse subsets of
leukemias and lymphomas, but also includes several myelomas, as well as smaller
subsets of cell lines from epithelial malignancies such as breast, lung, and GI cancers.
Each cell line has been infected with a lentiviral pool carrying 3 different DNA barcodes,
and each barcode consists of a 7-nucleotide DNA sequence. When genomic DNA is
extracted from a pool of barcoded lines, each of the 3 barcodes for a line is PCR
amplified during preparation for deep sequencing, allowing for triplicate measures of
each cell line in the competition assay. Barcoded cell lines are first cultured
independently until the competition assay. To begin a competition experiment, the
barcoded lines are pooled in approximately equal proportions. An initial aliquot is then
taken, to be used for determining the initial distribution of barcodes in the pool. Another
aliquot can then be placed into a vessel containing a control medium, or various vessels
that each contain the same medium but with a particular nutrient missing (Figure 2.1).
After ~2 weeks, aliquots are taken from the control and experimental vessels. Deep
sequencing of the initial, control, and experimental samples allows us to see how the
distribution of barcodes changed since the initial distribution, under both the control and
experimental conditions.
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Figure 2.1. Barcode-based competition assays for systematically mapping cancer
nutrient dependencies.
As multiple wild-type cell lines are known to be sensitive to asparagine depletion due to
insufficient expression of ASNS (108), we hypothesized that cancers may have diverse
responses to depletion of other non-essential amino acids as well. Thus, we attempted
to validate our large barcoded cell line library in vitro in a set of custom RPMI medias
that were each depleted in one non-essential amino acid. These flasks were cultured for
14-18 days, after which all flasks had undergone ~10 population doublings, and the
experiment was then processed for deep sequencing.
The results of this experiment are presented in Figure 2.2. During analysis of our data, it
was particularly informative to see which cell lines were represented in the sequencing
reads of the initial pool but not in the control or experimental pools. The growth rates of
these cell lines were likely too slow relative to other cell lines in these competitions, as
they were not represented even in the control condition after ~10 population doublings.
Thus, we could not obtain data for how these cell lines respond to nutrient depletions,
and we filtered these cell lines out of our pipeline, leaving 49 cell lines with robust
sequencing data for our final analysis. Notably, all of our ALL cell lines known to be
sensitive to asparagine depletion were filtered out during our analysis due to this type of
lack of representation in our control condition that suggested poor growth within
competitions. However, analyzing the data for other cell lines passing our filters did
show that cell lines respond quite differently to distinct amino acid depletions.
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Figure 2.2. Validation of a blood and lymphoid cancer barcoded-based cell
competition assay.
(Top) Heatmap of barcoded cell line responses to various amino acid deprivation
conditions. Data presented is the Log2 fold change in abundance from initial pool, of
barcodes (n=3) representing indicated cell lines in the competition assay, relative to the
control media condition.
(Middle) Barcoded cell line responses to serine depletion (mean ± SD, n=3 barcodes).
(Bottom-Left) Fold change in cell numbers (Log2) of a panel of wild-type cell lines used
in our barcoded competition experiment, after individual growth assays in various serine
concentrations for 5 days (mean ± SD, n=3).
(Bottom-Right) CCLE RNAseq expression levels of indicated genes involved in serine
synthesis.
For instance, simultaneous deprivation of aspartate and glutamate in one vessel, or of
proline and hydroxyproline in a different vessel, both had no discernible effects on cell
proliferation across all cell lines. In contrast, low glutamine, low tyrosine, and complete
serine depletion all caused subsets of the barcoded lines to drop out of the cell
11

competitions. Interestingly, there have been multiple recent reports on using
serine/glycine-depleted diets to slow the growth of cancers (112). We were intrigued by
the possibility that such diets could be used to treat some of the cancers that were
sensitive to serine depletion in our competition assay. Thus, we attempted to validate
our competition assay data for serine depletion by conducting independent proliferation
assays under serine depletion using a panel of cell lines.
Using a panel of 10 cell lines, we confirmed the existence of 5 cell lines that were
resistant to serine depletion and 5 lymphoma cell lines that were sensitive (Figure 2.2).
Whereas 2 sensitive cell lines arrested in serine-depleted media (U937 and DEL), 3 cell
lines strikingly underwent substantial cell death (KARPAS299, SUPM2, and SUDHL4).
We next looked at CCLE RNAseq data of these cell lines to determine whether low
expression of any particular gene involved in serine synthesis could explain these
growth responses to serine limitation. We found that KARPAS299, SUPM2, and
SUDHL4 had very low PHGDH mRNA expression levels. Interestingly, the sensitivities
of DEL and U937 to serine depletion were not explained by low CCLE expression of
genes known to be involved in serine synthesis, including PHGDH, PSAT1, PSPH,
SHMT1, or SHMT2. It is intriguing to consider why DEL and U937 are sensitive to
extracellular serine depletion despite normal basal expression of serine synthesis
pathway genes. One possibility is that these cell lines simply have a greater demand for
serine than other cell lines and that this demand cannot be met by intracellular
synthesis alone. If this is the case, then under serine limitation, the serine pools in these
cells may be insufficient for carrying out processes required for cell proliferation. For
example, if a cancer cell had a defect in glycine transport, then sufficient intracellular
serine may be needed for not only incorporating serine into new proteins but also for
maintaining glycine synthesis, as glycine is also required for protein synthesis as well as
for synthesizing purines (11). Ultimately, further work is needed to determine whether
DEL and U937 have specific metabolic vulnerabilities or demands that render them
particularly sensitive to serine limitation.
Of translational interest, we found that the CCLE data actually had several other
lymphoma cell lines with PHGDH levels that predict serine auxotrophy according to our
results. Interestingly, recent evidence showed that progression of in vivo lymphoma
models can be slowed using serine/glycine-depleted diets (112). We considered
whether the cancers represented by our serine auxotroph lymphoma cell lines could be
targeted with low serine/glycine diets, but noted that published serine/glycine-free diets
result in a circulating plasma serine concentration of ~50 µM instead of a true serinedepleted environment. In our data, the lymphoma cell lines found to be serine
auxotrophs can proliferate substantially at a media serine concentration of 30 µM. This
suggests that targeting such lymphomas in vivo may require the use of alternative
methods to achieve extracellular serine depletion, such as a serine-depleting enzyme
analogous to L-asparaginase.
Our experiments involving serine depletion validated that our barcode-based
competition assay allows us to identify cancers that are resistant and sensitive to
12

deprivation of a single amino acid. Furthermore, coupling this barcoding technique with
transcriptomics can help identify major genetic determinants of these growth responses,
as in the case of low PHGDH predicting serine auxotrophy. However, we were not able
to obtain a complete cell line sensitivity spectrum for L-asparaginase using this
technique in vitro, because many ALL cell lines appeared to grow too slowly in vitro for
sufficient barcode representation to remain even under control conditions at the end of
the competition assay. As in vitro growth rates of cell lines do not always predict in vivo
growth rates, we wondered whether these ALL cell lines could grow sufficiently in vivo
relative to our other barcoded cell lines such that an in vivo competition assay would be
possible. Furthermore, although ASNS expression is known to be a major determinant
of ASNase sensitivity, it remains unclear whether ASNS expression perfectly predicts in
vivo response to ASNase (113).
We determined that in vivo competition assays with our large barcoded cell line library
can be performed similarly to our in vitro competitions but with slight modification. Our
pool of barcoded cell lines can be injected as multiple subcutaneous tumors in NSG
mice, and mice can be divided into groups of control mice and mice treated with a drug
of choice such as ASNase. After 2 weeks of tumor growth, we harvest the tumor
xenografts, extract DNA from them, and process the DNA for sequencing as previously
described for our in vitro competition assays. One important output of this type of
experiment is the xenograft growth of these cell lines relative to each other. Some cell
lines have low reads across all tumors, and these are filtered out from the final analysis,
similarly to how we have to exclude slow growing cell lines in in vitro assays. However,
in contrast to what we observed in control flasks of our in vitro experiments, many of the
barcodes for ALL cell lines in our library are still represented in control tumors at
experimental endpoint.
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Figure 2.3. In vivo barcode-based cell competition assay for ASNase responses.
(Left) Schematic outlining
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remains the only cancer enriched at the ASNase-sensitive end. Despite the evidence
that ASNS expression is a reasonable predictor for ASNase response, we found cancer
cell lines with high expression of ASNS that appeared to have some sensitivity to
ASNase treatment in vivo, whereas some with low expression appeared resistant. For
instance, the chronic myeloid leukemia (CML) cell line BV173 was one of the 6 most
sensitive cell lines, despite having middle to high ASNS expression. To contrast, the
ALL line REH and the CML line EM2 had quite low ASNS expression but were not
sensitive to ASNase. Overall, these data demonstrate that our large library of barcoded
cell lines can be applied towards in vivo competition assays in order to systematically
map cancer responses to therapies or nutrient depletions. Furthermore, data from these
experiments can also be coupled with mRNA expression data to interrogate
determinants of assay response. Importantly, our results with this barcoded competition
assay system suggest that there may be factors other than ASNS that impact in vivo
ASNase response.
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Figure 2.5. ASNS expression is a reasonable, but imperfect, predictor of in vivo
ASNase sensitivity across hematopoietic and lymphoid cancer cell lines.
Log2 fold change in abundance from initial pool, of barcodes (n=3) representing
indicated cell lines in the competition assay, for ASNase-treated tumors (n=10) relative
to mean of vehicle-treated tumors (n=10). Boxes represent the median, and first and
third quartiles, and whiskers represent the minimum and maximum of all data points.
Statistics: FDR-adjusted P, by two-tailed unpaired t-test for unequal variances, of
ASNase tumor group versus vehicle tumor group. Individual CCLE RNAseq ASNS
expression levels of cell lines are also shown (x indicates no data available).
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sgGOT2:

2.2 CRISPR-based screen identifies metabolic genes whose loss sensitizes cells
to ASNase

gene score (asparaginase)

To further investigate the metabolic determinants of ASNase response, we performed
metabolism-focused CRISPR/Cas9-based screens in Jurkat, a T-ALL cell line resistant
in our in vivo competition assay (Figure 2.6). Consistent with the essential role of
asparagine synthesis under asparagine depletion, our screens yielded ASNS as the top
scoring gene, with 6 out of 8 ASNS guides differentially depleted under ASNase
treatment (Figures 2.7 and 2.8).
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Figure 2.6. CRISPR-based screen for metabolic determinants of ASNase
response.
(Left) Schematic depicting pooled CRISPR screen under ASNase treatment (0.25
U/mL) using a metabolism-focused sgRNA library.
(Right) Gene scores for Jurkat cells grown in untreated versus ASNase-treated vessels.
Most genes, as well as non-targeting control sgRNAs, gave similar scores in untreated
and treated vessels.
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In addition to ASNS, we noted scoring of TCA cycle genes fumarate hydratase (FH) and
malate dehydrogenase 2 (MDH2), as well as glutamic-oxaloacetic transaminase 2
(GOT2), highlighting a route to aspartate, the substrate for ASNS and precursor of
asparagine (Figures 2.7, 2.8, and 2.9). Furthermore, sgRNAs targeting solute carrier
family 1 member 5 (SLC1A5), the major glutamine transporter, and solute carrier family
25 member 12 (SLC25A12), a mitochondrial glutamate/aspartate exchanger, were also
significantly depleted under ASNase treatment (Figure 2.6). Since many cancers use
glutamine as a major anaplerotic source (115), our results confirm that the pathway
from glutamine uptake to asparagine synthesis through the oxidative TCA cycle is
necessary for maintaining cell proliferation under ASNase treatment (Figure 2.9).
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Figure 2.7. Top 25 metabolic genes differentially required under ASNase
treatment.
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Figure 2.8. CRISPR screen guide scores for top scoring genes.
Log2 fold change in the abundance of individual sgRNAs in untreated (black) or
ASNase-treated (gray) for the following top scoring genes in our CRISPR screen:
ASNS, TPK1, GOT2, MDH2, SLC1A5, SLC25A12, FH, and FLAD1.
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Figure 2.9. Top scoring genes in CRISPR screen highlight a specific route from
glutamine to asparagine as essential under ASNase treatment.

Interestingly, the second top-scoring gene in our screens was TPK1, for which all 8
guides were differentially depleted when we treated cells with ASNase (Figures 2.7 and
2.8). TPK1 is a ubiquitously expressed cytosolic kinase that uses imported thiamine and
ATP to produce TPP, the thiamine derivative that serves as a cofactor for many
enzymes, including AKGDH in the TCA cycle (116). To our surprise, TPK1, though
predicted to be a cell-essential gene, did not score under standard culture conditions,
suggesting the presence of sufficient TPP for proliferation. Given the lack of any
previous connection between thiamine metabolism and ASNase response, we next
focused on TPK1.
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CHAPTER 3. TPP enables de novo asparagine synthesis and proliferation under
ASNase treatment

3.1 TPK1-null cells are sensitized to ASNase treatment when supplemental TPP is
limiting
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To understand how TPK1 loss sensitizes leukemia cells to ASNase, we generated
CRISPR/Cas9-mediated clonal knockouts of TPK1, in which TPK1 protein levels were
undetectable (Figure 3.1). Interestingly, unlike in our genetic screening conditions,
TPK1 null Jurkat cells die in culture unless supplemented with TPP. This suggests that
TPP is indeed essential for proliferation, and that TPP from other cells with functional
TPK1 may have fueled the growth of TPK1 null cells during the course of the genetic
screens. To determine whether TPP limitation is sufficient to sensitize Jurkat cells to
ASNase, we first determined a TPP
dose that
Figure
2 enabled sub-optimal proliferation of TPK1
null cells under standard culture conditions (2.5 nM). At this dose, TPK1 null cells were
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A treatment compared
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significantly more sensitive to ASNase
controls (Figure
6
3.1), consistent with our screen results.
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Figure 3.2. Overexpression of sgRNA-resistant TPK1 cDNA rescues TPPdependence and TPP-dependent ASNase sensitivity of TPK1 KOs.
(Top) Immunoblot analysis of Vector Control, TPK1 knockout, and cDNA-rescued TPK1
knockout Jurkat cells. GAPDH was used as a loading control.
(Bottom) Fold change in cell number (log2) of cDNA-rescued TPK1 knockout Jurkat
cells, compared to that of cDNA-expressing Vector Control cells generated in parallel
and that of wild-type cells, after untreated or 0.0005 U/ml ASNase conditions for 5 days
(mean ± SD, n=3). Statistics: P < 0.05 by two-tailed unpaired t-test for equal variances,
for all 20 untreated-treated pairs.
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3.2 TPP allows asparagine synthesis from glutamine under extracellular
asparagine depletion
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Figure 3.3. [U-13C]-L-glutamine tracing in TPK1 KO cells and cDNA-rescued
counterparts in the presence and absence of TPP and asparagine.
(Top-Middle) Schematic depicting a metabolic route of asparagine synthesis from
glutamine. Filled circles represent 13C atoms derived from [U-13C]-glutamine.
(Rest) Abundance of indicated metabolites derived from labeled glutamine in Vector
Control, TPK1_KO1, and cDNA-rescued TPK1_KO1 Jurkats. Cells were incubated for
24 hours in media containing [U-13C]-glutamine (2 mM) in the presence or absence of
asparagine (378 µM) and TPP (3 µM). Colors indicate mass isotopomers (mean ± SD,
n=3).

In asparagine replete conditions, we did not detect any asparagine labeling, indicating
the lack of asparagine synthesis. In contrast, when asparagine was absent, ~50% of the
asparagine in parental cells, and TPK1 null cells supplemented with TPP or expressing
TPK1 cDNA, was derived from oxidative metabolism of [U-13C]-L-glutamine, in line with
ATF4-mediated upregulation of ASNS. Remarkably, in the absence of both asparagine
24

and TPP, we observed a substantial decrease in total as well as oxidatively labeled
(m+4) malate, aspartate, and asparagine in TPK1 null cells. Addition of TPP or
expression of TPK1 cDNA rescued all decreases in these metabolite levels. Strikingly,
TPK1 loss also led to the massive accumulation of alpha-ketoglutarate. Together with
the depletion of metabolites downstream from alpha-ketoglutarate, this is consistent
with the cofactor role of TPP for the AKGDH complex. Altogether, these metabolite
profiling data were in line with our genetic screen data by highlighting that utilization of
glutamine for the oxidative TCA cycle is essential for asparagine synthesis under
exogenous asparagine limitation in Jurkat cells. Furthermore, these results suggest that
by enabling AKGDH activity in the TCA cycle, TPP allows asparagine synthesis from
glutamine under the extracellular asparagine depletion.
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CHAPTER 4. Physiological thiamine is limiting for growth and ASNase response
of low SLC19A2 leukemia cells

4.1 Barcode-based competition assay identifies cell lines that grow sub-optimally
at low, physiologically-relevant thiamine concentrations
Given that thiamine-derived TPP availability enables growth under ASNase treatment,
we considered that conventional RPMI 1640 (RPMI) medium provides supraphysiological thiamine by supplying it at 3 µM. This is approximately 100-fold the
content of normal human plasma, which ranges from 6.6 to 43 nM (117). Building upon
the observation that TPK1 null cells display increased ASNase sensitivity under limiting
TPP concentrations, we explored two questions: first, that physiological thiamine levels
may be a growth limitation for a subset of cancer cell lines; and second, that culturing
such a subset in limiting thiamine environments may impact ASNase responses. To
address our first question, we decided to perform cell line competition assays in RPMI,
with and without added thiamine (supplemented with 10% dialyzed FBS). Notably, the
trace thiamine in dialyzed FBS leads to ~1 nM total thiamine in culture, which
approximates the content of human plasma.
As noted in Chapter 2, once individually-cultured barcoded cell lines have been pooled
together, this pool can be divided into many different conditions of interest. Although we
intended to focus on finding cancer cell lines for which the lower thiamine
concentrations of human plasma may be limiting, we decided to simultaneously test
responses of our barcoded cells to other vitamin limitations. Our rationale was an
unbiased one: we did not know beforehand whether any vitamin deprivation condition
could be limiting for some cancers while not affecting others, and testing multiple
conditions gave us an answer this question. Thus, rather than make only a control
medium and a low thiamine medium to grow barcoded pools in, I systematically made 7
custom RPMI medias that were each missing a single water-soluble vitamin normally
contained in RPMI. This was done by using the same base medium for each condition,
and by adding all but one vitamin to this base medium.
Although vitamins are essential nutrients for cell viability and growth, circulating human
blood contains very low levels of some vitamins, as exemplified by human plasma
having thiamine in the nanomolar range. These low levels of vitamins are still sufficient
for cellular metabolism and growth, likely because most vitamins are metabolized into
derivatives that serve as enzymatic cofactors rather than as cellular building blocks.
When we conducted barcoded competition assays in amino acid depletion conditions,
we had to note which amino acids were essential in culture. Conditions in which an
essential amino acid was depleted had to contain supplemental levels of the amino acid
that permitted mildly-inhibited cell proliferation. These supplemental amino acid
amounts were in the micromolar range. In contrast, for our vitamin limitation
competitions, we hypothesized that supplementation of media with even a dialyzed form
26
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of FBS would provide the minuscule amounts of a depleted vitamin needed for cells to
grow. We tested this in pilot experiments beforehand. Indeed, for most vitamins in
RPMI, it is possible to completely remove the vitamin from RPMI and cells will still grow
using the vitamin amount supplied solely by the supplemental dialyzed FBS. Thus, the 7
custom RPMIs I made that were each missing a vitamin were each simply combined
with 10% dialyzed FBS, and these were the final mediums used for cell competitions.
As a control, competitions were also grown in complete RPMI with 10% dialyzed FBS.

Figure 4.1. Barcode-based competition assay at conventional and lower,
physiologically-relevant thiamine concentrations and under other vitamin
depletions.
(Top) Heatmap of barcoded cell line responses to various vitamin deprivation
conditions. Data presented is the Log2 fold change in abundance from initial pool, of
barcodes (n=3) representing indicated cell lines in the competition assay, relative to the
control media condition.
(Bottom-Left) Barcoded cell line responses to thiamine depletion (mean ± SD, n=3
barcodes). Of note, cells were grown in the absence of thiamine (-thiamine), or in the
RPMI concentration of 3 µM thiamine (+thiamine). Media were supplemented with 10%
dialyzed FBS, which contributes ~1 nM thiamine.
(Bottom-Right) Relative abundance of thiamine in RPMI (containing 3 µM thiamine),
regular FBS (rFBS), and dialyzed FBS (dFBS) (mean ± SD, n=3), used to estimate the
thiamine contribution of each FBS when combined with thiamine-free RPMI.
The data for this systematic characterization of vitamin dependencies is presented in
Figure 4.1. Interestingly, for many vitamin depletion conditions, no cell lines seemed to
be affected by limitation of the vitamin. In fact, in low B12, low pantothenate, and low
pyridoxine, cells behaved almost identically to how they grew in control medium. In low
riboflavin, a few cell lines appear to have been actually mildly selected for, perhaps
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these cells had a relative growth advantage in this condition. In contrast, in low biotin,
low niacin, and low thiamine, we observed that subsets of cell lines seemed to drop out
of the cell competitions. This was intriguing, as it generally suggested a remarkable
heterogeneity among cancers in responding to low levels of these vitamins but not
others in our experiment. It is possible that in conditions like low B12, low pantothenate,
and low pyridoxine, the vitamin level was not low enough to affect cell proliferation.
These vitamins are all essential for human cells, and a low enough extracellular
concentration of these vitamins would likely slow proliferation. Our results suggest that
the trace amounts of these vitamins supplied by dialyzed FBS in our experiments was
actually sufficient to enable maximal cancer cell proliferation of all cell lines tested. It is
interesting to consider that cancer cell lines had heterogeneous responses to low levels
of certain vitamins. This could potentially be due to different vitamin transport
capabilities among cancer cell lines. For instance, it is possible that the cell lines that
were depleted in these competitions have low expression of high-affinity transporters of
these vitamins. If this is the case, it’s possible these vitamins can enter cells through
various low-affinity transporters under the excessive vitamin concentrations of RPMI,
whereas a high-affinity transporter may be required for optimal proliferation in lower
vitamin concentrations. Alternatively, it is possible that cell lines depleted in
competitions rely more on a specific vitamin-utilizing pathway for proliferation compared
to other lines. We know that inhibiting folate metabolism interrupts DNA synthesis,
which is essential for cell proliferation. Similarly, it is possible that depleting biotin,
niacin, or thiamine limits flux through one particular metabolic pathway that some
cancers greatly depend on for proliferation.
Of particular interest to us, many cancer cell lines grew similarly in control and low
thiamine conditions, but the fact that a small subset was depleted in the competition
assay specifically under low thiamine suggested that low thiamine content could limit
proliferation of some cancers as we had hoped to find.
We next determined whether the expression of any particular thiamine utilization gene is
predictive of growth responses to thiamine limitation. Correlating growth in low thiamine
with mRNA expression data of metabolic genes from CCLE revealed the plasma
membrane thiamine transporter SLC19A2 as a top scoring gene (Figure 4.2).
Expression of SLC19A3, the other canonical thiamine transporter, was not a predictor of
growth under low thiamine, and low mRNA levels of SLC19A3 compared to SLC19A2 in
CCLE (median TPM of 0.1 vs 6.6) suggested SLC19A2 may be the primary transporter
expressed in cancer lines.
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Given the connection between thiamine utilization and ASNase response, we next
asked whether cell lines with low SLC19A2 are more sensitive to ASNase in limiting
physiological thiamine than in the high thiamine of conventional media. To address this,
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we identified three B-ALL cell lines, KOPN8, REH, and NALM6, in which SLC19A2
mRNA was undetectable, consistent with CCLE data (Figure 4.4). We had previously
noted REH and NALM6 were ASNase-resistant in barcoded competitions in mice, but
we considered that the standard mouse chow weGenes
used may have supplied supraphysiological thiamine.
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Consistent with this, as we further lowered thiamine towards 10 to 40 nM to
be within
Thiamine
(nM)
the human plasma range, we found that for SLC19A2-low REH and NALM6 cells,
thiamine levels constrained growth and ASNase had a greater effect, compared to cells
cultured in supra-physiological thiamine (Figures 4.6 and 4.7). At 10 nM thiamine, live
REH cells were still visualized in ASNase-treated conditions (Figure 4.7). This is
consistent with the REH data shown in Figure 4.6 in which cells appeared to arrest
rather than die at 10 nM thiamine when ASNase-treated. Thus, at 10 nM thiamine, REH
cells can proliferate when untreated but appear to undergo stasis when treated with
ASNase. In contrast, SLC19A2-high Jurkat, RCH-ACV, and ST486 cells were
unaffected by physiological thiamine concentrations, and their ASNase response was
similar at high and low thiamine (Figure 4.6).
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Figure 4.6. SLC19A2 expression is a determinant of both growth and ASNase
response at physiological thiamine in a panel of cell lines.
(Top) Fold change in cell number (log2) of SLC19A2-high (Jurkat) and -low (NALM6,
REH) wild-type cell lines, after untreated or 0.001 U/ml ASNase conditions for 7-9 days,
at different thiamine concentrations added to thiamine-free RPMI supplemented with
10% double-dialyzed FBS (mean ± SD, n=3). P < 0.05 for untreated-treated pairs at
these thiamine concentrations: JURKAT- all concentrations, NALM6- all above 1.25 nM,
REH- all above 0 nM.
(Bottom) Independent experiment similar to that in (Top), showing fold change in cell
number (log2) of additional SLC19A2-high (ST486, RCH-ACV) wild-type cell lines
compared to SLC19A2-low NALM6, after untreated or 0.001 U/ml ASNase conditions
for 7 days, at different thiamine concentrations added to thiamine-free RPMI
supplemented with 10% double-dialyzed FBS (mean ± SD, n=3). Statistics: For NALM6
only, P < 0.05 by two-tailed unpaired t-test for equal variances, for all 5 untreatedtreated pairs.
Statistics: two-tailed unpaired t-test for equal variances.
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Statistics: two-tailed unpaired t-test for equal variances.

Taken together, these data establish SLC19A2 expression as a determinant of (1)
growth and (2) ASNase response at physiological thiamine levels.
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CHAPTER 5. Dietary thiamine intake influences ASNase sensitivity of low
SLC19A2 leukemia cells in vivo

5.1 SLC19A2 is the only detectable thiamine transporter in patient ALL samples,
and a subset of patients have low SLC19A2 tumors
To confirm that endogenously-low expression of SLC19A2 in cell lines is not a tissue
culture artifact, we probed for the existence of SLC19A2-low patient tumors. As ASNase
is a standard in the initial treatment phase of ALL, we explored RNAseq data of
pediatric primary ALLs sampled from peripheral blood and bone marrow, as well as
recurrent ALLs sampled from bone marrow (Figure 5.1).

Figure 5.1. Patient RNAseq data from TARGET ALL Sub-study.
RNAseq expression data for indicated genes, for various patient tumor samples from
ALL Expansion Phase 2 Sub-study of TARGET, and for every cell line in CCLE
(representing diverse tissue origins) for comparison.
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ASNS, TPK1, and SLC19A2 mRNAs were consistently detected in these 3 datasets
(Figure 5.1), and their expression was similar between primary and recurrent bone
marrow datasets, suggesting that treatment generally did not influence mRNA levels of
these genes. Of note, SLC19A3 mRNA was very rarely detected, indicating that
SLC19A2 is likely the primary thiamine transporter expressed in these tumors, similar to
that seen across CCLE cell lines. Importantly, these data show a diverse range of
SLC19A2 expression among patients and confirm the existence of low SLC19A2 tumors
in which ASNase response may depend on environmental thiamine.

5.2 Humanizing blood thiamine of mice through diet sensitizes low SLC19A2 ALL
cells to ASNase in vivo
We next asked whether extracellular thiamine availability also affects ASNase response
of SLC19A2-low leukemia cells in vivo. To create a model of such tumors, we used the
SLC19A2-low REH cell line and generated orthotopic tumors in NOD-SCID gamma
(NSG) mice. First, mice that were on the conventional chow-based diet used in our
barcoded competition experiment were placed on a purified ingredients diet with either a
high thiamine amount to mimic the supra-physiological plasma thiamine levels obtained
with chow, or a low amount that resulted in levels resembling that of human serum
(Figure 5.2, Table 5.1).
Importantly, it is also possible to maintain supra-physiological blood thiamine levels in
humans. In the clinic, supplemental thiamine is usually administered when thiamine
deficiency is suspected. However, prophylactic use has been recommended for other
scenarios, such as for preventing malignancy-associated thiamine deficiency (118, 119)
or for cases of malnutrition such as patients struggling with alcohol dependency (120).
There is no standard regimen for clinical thiamine supplementation even for cases of
deficiency (120-122). In a study that evaluated thiamine supplementation regimens
used in out-patient management of alcohol dependency, a total daily administration of
500 mg thiamine by intramuscular or oral routes led to plasma thiamine levels ~10-fold
and ~8-fold greater than normal levels, respectively (123). These regimens were given
for 11 days, and these supra-physiological levels were maintained over the majority of
this timeframe. Even higher plasma thiamine levels (~100-fold of normal) have been
observed transiently after fast intravenous administration of less than 500 mg thiamine
(117, 124), and intravenous regimens are recommended when deficiency is suspected
(120-122). Of note, 500 mg thiamine tablets are commercially available for dietary
supplementation, with suppliers recommending daily intake of these tablets. Thus, it is
plausible to consider that supra-physiological plasma thiamine could be reached in a
cancer patient not only through clinical prophylactic regimens aimed at preventing
malnutrition, but also through consumption of readily-available dietary supplements.
Lowering plasma thiamine to human levels was well-tolerated, as indicated by animal
weights remaining unchanged after diet modification (Figure 5.2). We then engrafted
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REH cells in mice on either high or low thiamine diets, and tested the efficacy of
ASNase treatment in each of these cohorts. Importantly, our ASNase regimen depleted
plasma asparagine levels without affecting the levels of abundant amino acids such as
glutamine (Figure 5.3).

Figure 5.2. Humanizing plasma thiamine levels in mice by lowering thiamine
content of diet.
(Left) Plasma thiamine profiling of mice on conventional chow (n=3 mice), and mice on
a modified AIN-93G purified diet of low thiamine content (n=8 mice) (mean ± SD).
Human serum was profiled simultaneously for relative comparison. Statistics: *P < 0.01
by two-tailed unpaired t-test for unequal variances.
(Middle) Weights of mice initially on conventional chow, then switched to standard AIN3G purified diet for 1 week, and finally switched to a modified AIN-93G purified diet of
low thiamine content (n=8 mice) for indicated times, relative to initial weights on chow
(mean ± SD).
(Right) Plasma thiamine profiling of mice on conventional chow (n=4 mice), and mice on
a modified AIN-93G purified diet of high thiamine content (n=4 mice) (mean ± SD).
Statistics: two-tailed unpaired t-test for unequal variances.
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Figure 5.3. Alternative ASNase regimen in mice with less frequent administration.
Relative abundance of indicated amino acids detected in plasma of mice on purified diet
AIN-93G containing high thiamine, before treatment (gray) and after 1000 U/kg
ASNase. Plasma was collected after a single dose, at days 1 (orange) and 4 (pink) after
administration (mean ± SD, n=3 mice), and because asparagine remained depleted
after 4 days, mice were treated only twice weekly in the xenograft survival experiments.
Of note, glutamine was not depleted at either time-point.

Compared to the high thiamine diet group in which plasma thiamine was comparable to
that seen with standard chow, neither ASNase treatment or lowering dietary thiamine
alone significantly affected survival from leukemia (Figure 5.4). Of note, proliferation of
these leukemia cells slowed under low thiamine conditions in vitro, raising the possibility
that the in vivo microenvironment that cells were directly exposed to may not contain
low enough thiamine to impair growth. Remarkably, however, combining ASNase
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Figure 5.4. ASNase significantly increases survival of mice bearing orthotopic
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(Right) Box and whisker plots of survival data.
Statistics: (Left) n.s. = Mantel-Cox P > 0.05 / 3 (Bonferroni correction),
and (Right) n.s. =
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two-tailed unpaired t-test for equal variances P > 0.05 / 3 (Bonferroni correction). For
both analyses, **P < 0.005. n=5 mice for untreated groups and n=7 mice for ASNase
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Altogether, our results provide evidence that thiamine availability resulting from dietary
intake can impact ASNase
sensitivity of low SLC19A2 ALLs in vivo.
ASNASE
ASNASE
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CHAPTER 6. Discussion
In previous studies, a cell competition assay of 28 barcoded cell lines representing
various cancer types had shown that growth of different cancers can vary greatly under
nutrient limitations such as low glucose and low cholesterol (3, 125). In this work, I
helped expand this library of barcoded cell lines by both lentivirally infecting more cell
lines with barcodes and by validating that all cell lines in our final library had correctly
annotated barcodes. This resulted in a comprehensive list of more than 60 barcoded
cell lines, mainly representing cancers of hematopoietic and lymphoid tissues. Cancers
of these origins were of particular interest to us, as leukemias such as ALLs have
already been treated successfully in the past through the depletion of circulating
nutrients. This is best exemplified by the clinical success of ASNase even as a
monotherapy for ALL, and also by the more recent use of arginase for certain AMLs
(126). Thus, it is possible that there may be other unknown, clinically-relevant nutrient
dependencies still to be mapped among cancers of blood and lymphoid origins.
Importantly, we validated that our large barcoded cell line library could indeed be used
for in vitro cell competitions, but also for in vivo competitions by injection of barcoded
pools as subcutaneous xenografts in mice. This methodology can now be applied not
only towards mapping responses to nutrient deprivation conditions, but also towards
testing novel drug treatments across these cancer cell lines.
Here, we first applied our barcoded cell line assay towards a systematic mapping of
cancer cell responses to the depletion of individual non-essential amino acids (NEAAs)
in vitro. To do this, we simultaneously made 9 custom RPMI medias, where each was
missing only 1 or 2 NEAAs, and grew barcoded pools under these different conditions.
In our assays, there were some conditions in which no cell lines were affected, such as
in aspartate/glutamate-free media, as well as in proline/hydroxyproline-free media. In
contrast, we observed that in low tyrosine, low glutamine, and complete serine
depletion, a subset of barcoded cell lines proliferated less than in control conditions.
This raised the possibility that some of these cancers could be targeted by limiting the
extracellular availability of one of these amino acids. Serine/glycine-depleted diets have
already been shown to slow the growth of certain cancers (112), and we were intrigued
by the possibility of identifying additional cancers that could benefit from this dietary
intervention. Thus, we turned towards validating our low serine competition assay
results as a means of determining whether our large barcoded cell line technique could
indeed yield robust data on cellular nutrient dependencies.
We attempted to validate the results of our in vitro serine depletion competition by
conducting individual growth assays of cell lines that had been used in our barcoded
experiment. Remarkably, we confirmed that five lymphoma cell lines that had dropped
out of the cell competitions in low serine were in fact incredibly sensitive to serine
restriction compared to five control cell lines. Among these cell lines sensitive to serine
restriction were two cell lines that arrested at low serine and three cell lines that
appeared to be complete serine auxotrophs incapable of surviving without extracellular
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serine availability. These three serine auxotrophic cell lines had very low basal PHGDH
expression in CCLE RNAseq data. However, the other two lymphoma cell lines that
arrested at low serine did not have low expression of PHGDH or other genes known to
be involved in serine synthesis. Further experiments are needed to truly rule out a
defect in serine synthesis in these lines, such as a probing for the ability to upregulate
serine synthesis genes in these cancer cells. If these cells do not have a defect in
serine synthesis, it is possible that they have a substantially greater demand for serine
than other cell lines. Another interesting observation was that 4 out of 5 of the cell lines
we identified as sensitive to serine depletion were also previously confirmed to be
cholesterol auxotrophs by our lab (125). Cholesterol auxotrophy in some of these cell
lines was associated with promoter hypermethylation of a cholesterol synthesis pathway
gene, and it is possible that serine synthesis gene promoters are similarly methylated in
these cancer cells.
Although we thought these cancers could potentially be targeted with serine/glycinedepleted diets in vivo, we noted that these diets do not fully deplete circulating serine
but instead bring it down to ~50 µM in serum (112). However, even at ~30 µM serine in
vitro, these lymphoma cell lines still undergo multiple population doublings in a matter of
days. It appears that a method of completely depleting circulating serine, down to levels
below 3 µM based on our data, is needed to target these serine auxotrophic cancer
cells. Such depletion could perhaps be achieved by a serine-depleting enzyme
analogous to ASNase, which has been previously proposed (127). A method for
depleting serine is indeed warranted, as further analysis revealed that there’s as many
lymphoma cell lines with CCLE PHGDH levels that predict serine auxotrophy as there
are ALL cell lines with CCLE ASNS levels that predict ASNase sensitivity.
Through our work with serine depletion, we validated that our large barcoded
competition assay can indeed pinpoint cancers that are resistant and sensitive to a
particular nutrient depletion. Furthermore, coupling our competition assay responses
with gene expression data proved to be very valuable in elucidating determinants of
growth in nutrient deprivation. As ASNase is an established nutrient-depleting therapy
already in use for ALLs, we were interested in mapping responses of other blood and
lymphoid cancers to ASNase and also in determining pathways essential for ASNase
resistance. We noted that many ALL cell lines in our barcoded library had been
previously reported to be ASNase-sensitive and could serve as useful control cell lines
in a competition grown under ASNase treatment. One challenge we encountered,
however, was that these ALL cell lines grew too slowly in vitro to be represented even in
control competition pools after several population doublings. However, we hypothesized
that most cell lines in our barcoded library may undergo some change in doubling time
when grown in vivo, which would perhaps permit ALL cells to persist through the course
of the assay.
Thus, we grew barcoded cell line pools as subcutaneous xenografts in mice that were
divided into control and ASNase treated groups. This resulted in a comprehensive
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mapping of the in vivo responses of 62 cell lines to ASNase. We had thought there may
be other cancers besides ALLs that may benefit from ASNase therapy. To our surprise,
across all of the different blood and lymphoid cancer types represented in our barcoded
library, the ASNase-sensitive end of the response spectrum contained almost
exclusively ALL cell lines. Thus, our data did not identify other cancer types that may
benefit from ASNase monotherapy, but instead further emphasized that asparagine
auxotrophy is a phenomenom that is intriguingly unique to ALLs. Importantly, this
compendium of cell line response to ASNase allowed us to interrogate potential
determinants of ASNase sensitivity in an effort to identify pathways that may be
essential under ASNase treatment. Using CCLE mRNA expression data, we found that
5 of the 6 most sensitive cell lines in our experiment were ALLs that expressed low
basal ASNS levels. This was consistent with basal ASNS expression being a known
major determinant of the cellular response to asparagine depletion. Although basal
ASNS expression did appear to predict many of the growth responses in our data, it
was not a perfect predictor, and our data suggested there may be additional
determinants of ASNase sensitivity.
In order to further elucidate determinants of ASNase response, we performed a
negative selection genetic screen to identify genes that are required for maintaining
ASNase resistance in the Jurkat T-ALL cell line. This cell line was appropriate for this
screen because it was one of the few ALLs in our in vivo competition assay that was not
sensitive to ASNase. As discussed previously, there is already evidence that increasing
the availability of certain nutrients through diet can affect response to a different
component of ALL therapy, the DHFR inhibitor methotrexate. Thus, we were particularly
interested in seeing whether utilization of any particular nutrients affects response to
ASNase in ALLs. Our metabolism-focused sgRNA library was well-suited to investigate
this question, as it targets many transporters and enzymes involved in nutrient uptake
and processing.
Consistent with our barcoded competition assay highlighting the importance of ASNS
expression under ASNase treatment, ASNS was the top hit of our genetic screen.
ASNS is the final step in de novo asparagine synthesis, and as discussed in detail in
Chapter 2, several other scoring genes appeared to delineate a particular metabolic
route as essential for providing the aspartate substrates used by ASNS to make
asparagine. In brief, these genes were SLC1A5, SLC25A12, FH, MDH2, and GOT2.
The scoring of these genes suggested that glutamine is taken up by Jurkat cells,
metabolized through the forward TCA cycle to produce oxaloacetate, and that
oxaloacetate is then converted to aspartate. The results of our genetic screen were
intriguing for multiple reasons.
Firstly, many cancer types have been shown to utilize glutamine for filling their TCA
cycle (a process termed glutamine anaplerosis) (115). Thus, the results of our genetic
screen may delineate a pathway towards asparagine used by other cancer types.
Secondly, although the aforementioned genes along this pathway all scored strongly,
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the second top hit in our screen was actually a gene that does not directly interact with
an asparagine precursor. This gene was TPK1, which encodes the kinase that converts
the vitamin thiamine into its activated derivative TPP.
TPP is used as a cofactor in several metabolic enzyme complexes, but our screen
suggested that its role under ASNase treatment was likely to enable the activity of
AKGDH in the TCA cycle. As TPP is derived from thiamine, an essential nutrient that
must be obtained from the environment, we became interested in determining whether
extracellular availability of thiamine may influence ASNase sensitivity of glutamineanaplerotic cells. We felt this would be a significant finding, as there are only a few
reported cases in which a nutrient affects therapy. Furthermore, it would mean that
more than one component of ALL therapy could be influenced by a nutrient obtained
through diet. To begin to answer whether thiamine availability affects ASNase response,
we first aimed to confirm that maintaining TPP levels through TPK1 is essential for
growth under ASNase.
Thiamine, as a vitamin, is a dietary requirement in humans, and its only established
physiological role is to become TPP for use as a cofactor (116). TPK1 is the only
enzyme known to convert thiamine to TPP in humans. Thus, we anticipated that TPK1
would be an essential gene in cultured cells, and to our knowledge, full TPK1 knockouts
in a human cell line have never been reported. Intriguingly, TPK1 did not appear to be
essential based on the sgRNA readouts of our genetic screen. Abundance of sgRNAs
targeting TPK1 did not change in the untreated condition of our genetic screen after
several doublings. We hypothesized that this may be due to multiple reasons. Free TPP
may have been present in the screening media due to release from dead or live cells. In
later experiments, we ruled out that FBS contributed significant TPP in our screens, as
even mixed population TPK1 KOs cannot grow in cell culture media supplemented with
regular FBS. An additional consideration is that the half-life of TPP in cells may be on
the order of several days (128). Regardless of its source, if free TPP was present in the
media, then TPK1 KOs would need to have a TPP transporter to utilize this source,
which to date appears to have only been described in colonocytes (129). Overall, the
observation of TPK1 appearing non-lethal in our screen was puzzling, but had important
implications for interpretation of gene essentiality screens. In large datasets of
essentiality screens, it is possible that some metabolic genes will not appear as
essential if the product of this gene is present in sufficient quantity in the media due to
release from other cells or as a component of the cell culture media itself. To us, the
most intriguing aspect of these TPK1 screen results were that a therapeutic window
appeared to exist where cells could have enough TPP to proliferate, unless treated with
ASNase.
By supplementing TPP in cell culture media, I was able to successfully generate
CRISPR/Cas9-mediated clonal knockouts of TPK1 using the Jurkat cell line. We found
that loss of TPK1 is indeed lethal but that with sufficient exogenous TPP, TPK1 KO cells
could be made to proliferate at the same level as their WT counterparts. Only
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nanomolar amounts of TPP were necessary to rescue TPK1 KOs from death,
suggesting the presence of a high-affinity TPP transporter in Jurkat cells. Our TPK1
KOs could perhaps be used to identify such a transporter using a secondary genetic
screen for genes required for these KOs to proliferate under minimal supplemental TPP.
Furthermore, these KOs can be used by others for studying the various metabolic
processes dependent on TPP. In our work, we focused on validating that TPP
availability enables de novo asparagine synthesis and ASNase resistance.
To perform cell proliferation assays with TPK1 KOs, I found a minimum media
concentration of supplemental TPP that would allow for routine culture of these cells,
which resulted in similar doubling times as parental cells. Importantly, this minimum
concentration allows for plating growth assays in which TPK1 KOs die within 5 days,
which is a typical length for a cell proliferation experiment. Thus, these cell culture
practices can now be easily used by others to determine the influence of TPP
availability on cellular processes of interest. To determine whether TPP availability
affects ASNase response, I then established a range of TPP concentrations in which
TPK1 KOs would go from death, to mild proliferation, to a proliferation rate that was only
mildly growth-limiting relative to the growth of both KO clones in high-dose TPP and
parental controls. This range was narrow and on the nanomolar level (0 to 5 nM),
demonstrating the potent effect of TPP on the viability of cells, and further illustrating the
presence of an unknown high-affinity TPP transporter. Furthermore, this range was near
the human plasma range of thiamine (6.6 to 43 nM), which suggested that our
experiments within these conditions may have physiological relevance. To validate the
results of our ASNase genetic screen, we performed proliferation assays of TPK1 KOs
in 0 to 5 nM TPP in the presence and absence of ASNase. Interestingly, when
supplemental TPP was limiting for proliferation, cells became significantly sensitized to
ASNase. Finally, we confirmed that the effects of TPP limitation on both general growth
and ASNase response of KO clones could be rescued by overexpressing a sgRNAresistant TPK1 cDNA, validating the results of our genetic screen.
Having established that TPP does indeed enable growth under ASNase treatment, we
next aimed to test whether this is due to TPP being required for AKGDH activity during
utilization of extracellular glutamine to make asparagine. As detailed in Chapter 3, we
performed glutamine tracing studies to answer this question. The results of this were
consistent with our genetic screen results that suggested a metabolic pathway from
extracellular glutamine to intracellular asparagine is essential under asparagine
depletion by ASNase. Furthermore, our data pinpointed that the role of TPP during this
response to ASNase treatment is indeed to enable the activity of AKGDH. In some
cancers, alpha-ketoglutarate derived from glutamine can proceed in the reverse
direction of the TCA cycle to make citrate, in a process called reductive carboxylation
(130). Citrate could then be exported to the cytoplasm to be used to generate
oxaloacetate via ACLY, which could then proceed through GOT1 and ASNS to generate
asparagine as an adaptation to asparagine depletion. However, in our experiments,
labeling suggested that citrate is primarily derived through forward TCA in Jurkat cells.
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Furthermore, the minimal M+3 asparagine labeling in our data suggested that Jurkat
cells do not generate substantial asparagine through a reverse TCA route. Thus, our
data suggests that TPP is essential for the primary metabolic pathway that these cells
can utilize to make asparagine from glutamine. This could potentially be the case in
other glutamine-anaplerotic cancers as well.
Overall, our studies with TPK1 KOs demonstrated that TPP enables asparagine
synthesis under extracellular asparagine depletion, and consequently, that sufficient
TPP is needed for maximal ASNase resistance. Supplemental TPP was mildly growthlimiting for TPK1 KOs at extracellular concentrations that were similar to the normal
concentration of thiamine in human plasma, and ASNase sensitivity was exacerbated
when TPP was limiting. We hypothesized that there may be some cancers for which
physiological thiamine levels are limiting, and that these cancers may have increased
ASNase sensitivity at these limiting concentrations relative to when in supraphysiological thiamine concentrations like that found in conventional media. To first test
whether physiologically-relevant thiamine levels could be growth-limiting for some
cancers, we decided to apply our barcoded competition assay technique. Whether a
vitamin can be growth-limiting at physiological concentrations, such that excess
supplementation could exacerbate its growth, was an interesting concept that appeared
to be largely understudied. Thus, we decided to study barcoded cell line responses to
not only in vitro limitation of thiamine, but also of other vitamins.
Interestingly, we found that in low thiamine, low biotin, and low niacin, subsets of cancer
cell lines were particularly sensitive to the vitamin limitation. These cancer types may
have defects in vitamin utilization processes such as import, causing them to require
greater extracellular availability of a particular vitamin to obtain sufficient intracellular
pools for maximal proliferation. Alternatively, it is possible that these cancers have a
greater dependence on particular metabolic pathways that require a vitamin-derived
cofactor. Overall, this dataset provided a mapping of how several cancer types respond
to fluctuating vitamin levels, and demonstrated that some cancers can be more
dependent on extracellular vitamin levels than others. Further study of why some
cancers have increased dependencies on biotin and niacin is needed, but we next
focused on investigating why certain cancers exhibited sub-optimal proliferation when
media thiamine was lowered to physiologically-relevant concentrations.
Correlating the barcoded competition assay growth responses in low thiamine with
CCLE mRNA expression data of metabolic genes gave thiamine transporter SLC19A2
as a top hit. To further support this data, we also performed a CRISPR/Cas9-based
metabolism-focused genetic screen for genes essential for growth in low thiamine.
SLC19A2 also scored in this functional screen, suggesting SLC19A2 expression does
indeed influence growth capacity at low, physiologically-relevant thiamine levels.
Interestingly, previous work had shown that the thiamine transporters SLC19A2 and
SLC19A3 were expressed in lower levels in some breast and lung cancers relative to
normal tissue counterparts (13, 131). Follow-up work showed that breast cancers with
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low SLC19A3 may have increased dependence on extracellular thiamine, a
dependency that can potentially be exploited by thiamine depletion with the drug
thiaminase (14). Thiaminase was also found to have a cytotoxic effect in other cancer
types, including leukemias, likely due to the general essentiality of thiamine for cell
viability (16, 132). Interestingly, our analysis of the ~1,000 cell lines in CCLE suggested
that SLC19A3 is not expressed in most cancer cell lines. This suggests that SLC19A2 is
the primary known thiamine transporter in most cancers. Additionally, our barcoded
competition assay and genetic screen approaches both suggested that expression of
SLC19A2 is a major determinant of cellular growth under thiamine limitation.
Thiaminase-induced depletion can be toxic over time (14), but our data suggested that
physiologically-relevant thiamine concentrations could already be growth-limiting for
some cancers with low SLC19A2. As mildly-limiting TPP availability was sufficient to
sensitize TPK1 KOs to ASNase, we next aimed to test whether physiological thiamine
could be limiting for both growth and ASNase response of SLC19A2-low cancer cells.
We next identified multiple SLC19A2-low ALL cancer cell lines. Two of the SLC19A2low cell lines identified, REH and NALM6, were notable as being some of the few
ASNase-resistant ALL cell lines in our in vivo barcoded competition. We hypothesized
that lowering extracellular thiamine to physiological levels could be limiting for these
SLC19A2-low cell lines, and would sensitize them to ASNase. Indeed, simply lowering
media thiamine ~100-fold from standard RPMI concentration to a more physiological
level led to thiamine becoming slightly growth-limiting for REH, which was associated
with a greater ASNase response. Furthermore, expressing a SLC19A2 cDNA in REH
was sufficient to rescue both the sub-optimal growth and increased ASNase sensitivity
seen at lower thiamine. As detailed in Chapter 4, we went on to confirm in a panel of
wild-type cell lines that SLC19A2 was in fact a determinant of growth and ASNase
response at human plasma thiamine concentrations. Additionally, SLC19A2 was
necessary for SLC19A2-high cells to maintain maximal growth and ASNase resistance
at physiological thiamine. Of translational importance, we also found that low expression
of SLC19A2 was not a phenomenon solely observed in cultured cells. By analyzing
human ALL tumor mRNA expression data, we first confirmed that SLC19A3 is largely
not expressed in these human tumors, suggesting that SLC19A2 is the primary thiamine
transporter in these ALLs. Finally, we confirmed that patient tumors exhibit a range of
SLC19A2 expression and that SLC19A2-low tumors do in fact exist, consistent with
CCLE cell line data.
We next aimed to test whether extracellular thiamine affects ASNase response of
SLC19A2-low cells in vivo. To do this, we first had to determine how to modulate
circulating plasma thiamine in mice through diet. This posed a challenge, as it is well
known that dietary thiamine deficiency is toxic in humans, and thiaminase administration
in mice had been shown to have some toxicity over time. However, our cell culture
experiments suggested that we did not have to cause a thiamine deficient state to
sensitize cancers to ASNase. Instead, our in vitro data suggested that SLC19A2-low
cells intriguingly already have an inherent ASNase sensitivity at physiological thiamine
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levels, which can be inadvertently rescued through excess thiamine supplementation.
Thus, we aimed to determine whether physiological human thiamine plasma
concentrations are already sufficient to sensitize SLC19A2-low leukemia cells to
ASNase in an in vivo model. We had observed that SLC19A2-low REH cells were
ASNase-resistant when engrafted in mice fed standard chow and when grown in media
containing supra-physiological thiamine, but that humanizing thiamine levels in vitro
sensitized these cells to ASNase. Thus, we hypothesized that standard mouse chow
contained supra-physiological thiamine levels and that SLC19A2-low cells would be
more sensitive to ASNase if circulating thiamine was humanized. Plasma profiling
revealed that standard mouse chow did indeed cause plasma of mice to have orders of
magnitude more thiamine than human serum. This suggested that many research
facilities may be using standard mouse diets that inadvertently over-supplement
thiamine. As thiamine-derived TPP is involved in many metabolic processes, further
work is perhaps warranted to determine the effects of such practices on organismal and
cellular metabolism.
To determine whether I could humanize plasma thiamine levels of mice, I conducted
several experiments using purified ingredients diet pellets that were custom-made to be
thiamine-free. While mice groups were fed this diet, I supplied various amounts of
thiamine in their water bottles to determine whether I could achieve human plasma
thiamine levels without adverse effects. I found that it was indeed possible to achieve a
human thiamine plasma level of ~10 nM in mice without causing any weight loss or
other observable adverse reactions. The diet used to achieve these plasma levels
consisted of thiamine-free purified pellets combined with a low thiamine amount within
mouse water bottles, and the amount provided in water could be raised to obtain an
appropriate high-thiamine control diet. In the end, I had a Low Thiamine diet that
resulted in a circulating thiamine content comparable to that of human serum, and a
High Thiamine diet that differed only in water thiamine content. Furthermore, this High
Thiamine diet was designed to mimic plasma thiamine levels obtained with standard
mouse chow. To our knowledge, no other mouse diets currently exist for providing
circulating thiamine at the level of human plasma. This physiological low thiamine diet,
and its high thiamine diet control, may be of value to others studying the effects of
thiamine availability on biological processes in vivo.
After developing these diets that allowed us to modulate plasma thiamine levels, our
Low Thiamine and High Thiamine diets were fed to NSG mice. We subsequently
administered SLC19A2-low REH cells by tail-vein to these mice to form orthotopic ALL
xenografts. Compared to the High Thiamine group that had circulating plasma thiamine
levels comparable to that obtained with standard chow, neither lowering dietary
thiamine or treatment with ASNase caused a significant effect on survival from
leukemia. Remarkably, combining a lower dietary thiamine intake with ASNase
treatment did significantly extend survival. Together with our in vitro experiments, our
results demonstrate that lowering thiamine to human physiological levels in culture
media, and in mouse plasma through diet, increases the response of a subset of cancer
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cell lines to ASNase, an important chemotherapeutic in the treatment of ALL (Figure
6.1). This subset is defined by low expression of SLC19A2, the primary thiamine
transporter in ALL tumor samples.

Figure 6.1. Environmental thiamine influences ASNase sensitivity in a subset of
leukemia cells with low SLC19A2 expression.

This work raises the possibility that low SLC19A2 expression may be associated with
greater patient response to ASNase. Importantly, however, increasing blood thiamine
concentrations through excess supplementation could diminish ASNase efficacy in such
cancers. More broadly, this thesis provides a proof of principle that humanizing the
vitamin levels of both in vitro and in vivo models can affect therapeutic sensitivity of
cancers that have specific vitamin utilization deficiencies.

49

CHAPTER 7. Future directions and perspectives

7.1 Relevance to vitamin supplementation during cancer treatment
Our results suggest that extracellular thiamine availability influences ASNase response
of a subset of leukemia cells. Indeed, when combined with a change in dietary thiamine
intake, ASNase treatment extends survival in a mouse leukemia model. It is important to
note that the low thiamine dietary intervention used here was equivalent to simply
maintaining normal human serum levels, and was sufficient to sensitize SLC19A2-low
leukemia cells to ASNase. Lowering thiamine levels further than the normal
physiological range for therapeutic purposes in experimental or clinical settings would
likely have adverse consequences, due to the diverse functions of TPP in normal cell
types. In addition to its role in the AKGDH complex, TPP serves as a cofactor for
various other enzymes, including the pyruvate dehydrogenase (PDH) complex, the
branched-chain alpha-ketoacid dehydrogenase complex, and transketolase (133). Thus,
biochemical abnormalities, such as lactic acidosis resulting from diminished PDH
activity, are among the symptoms observed in patients with nutritional thiamine
deficiency (133-135).
Although high thiamine supplementation is warranted in cases of deficiency,
prophylactic use has been suggested with limited evidence for other scenarios,
including preventing potential side effects of adult ASNase administration (136, 137).
Such use in ALL patients should therefore be weighed with the possibility that excess
blood thiamine may negatively impact ASNase response of a subset of cancers.
However, human studies are needed to further elucidate the effect of excess thiamine
on therapeutic response. To determine whether SLC19A2 expression is predictive of
responses to ASNase-containing regimens and patient survival, it would be necessary
to measure patient plasma thiamine levels during treatment since having supraphysiological levels could affect response. Another possibility is to document vitamin
supplementation during clinical trials, which has been done for those with antioxidant
properties like vitamin E, and their use is now discouraged while undergoing
chemotherapy and radiotherapy for various cancers (138-140). Collectively, our work
adds to the growing list of studies available that probe whether excess vitamin
supplementation may be detrimental during chemotherapy (141). Unfortunately, the lack
of clinical reports on this topic has translated to non-uniform physician advice with
regards to taking vitamin regimens during cancer treatment (142, 143).
7.2 Implications for vitamin use in pre-clinical in vitro and in vivo studies
Our work emphasizes the need to better recapitulate tumor nutrient environment in vitro.
Conventional cell culture media are complex, containing both proteinogenic and nonproteinogenic amino acids, important polar metabolites such as glucose and
glutathione, inorganic salts such as NaCl, trace elements, and of course, essential
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vitamins. Recently, custom media have been designed to contain physiologicallyrelevant concentrations of these components. However, it is important to note some of
the limitations of these physiological media, and what can be done to better simulate
nutrient environments in the future.
Physiological environments, such as that of blood plasma, contain many more
metabolites than that found in synthetic culture media. Thus, quite reasonably, recent
reports of plasma-like media focused on manipulating only a portion of the metabolome
found in human plasma. This is partly due to the fact that nutrients in cell culture
systems are provided not only through the synthetic media itself, but also through the
supplementation of media with various percentages of fetal bovine serum (FBS). FBS
provides compounds essential for cell proliferation that are not present in chemically
defined media, such as lipids and additional micronutrients. FBS can also be treated to
yield variations with distinct metabolite profiles such as lipid-depleted FBS obtained by
charcoal-stripping, or small-molecule-depleted FBS resulting from extensive dialysis (as
used in this work). To date, cell culture media designed to mimic human plasma have
been supplemented with either a low percentage (2.5%) of regular FBS, or a
conventional percentage (10%) of dialyzed FBS (9, 144). These FBS practices
contribute low amounts of the small molecule metabolites that are already present at
defined, desired concentrations in the synthetic media. Thus, the final complete media
that results does indeed contain human plasma-like levels of the metabolites considered
in the synthetic media design. However, it remains unclear how the final media
concentrations of other metabolites, such as lipids, compare to that of human plasma.
Additionally, these recent plasma-like media studies did not attempt to mimic the vitamin
concentrations of human plasma, and vitamin levels in these media remain at the supraphysiological concentrations found in conventional media. To contrast, the work
described here only manipulated cell culture media so that it contained human plasma
levels of thiamine, and the levels of other vitamins and metabolites in our experiments
remained at conventional cell culture concentrations. However, manipulating the levels
of thiamine alone caused significant changes in leukemia cell responses to an important
therapeutic, demonstrating a need for considering vitamins during physiological media
design. Future development of plasma-like media should improve upon the important
recent variations, by attempting to humanize the levels of additional metabolites such as
lipids and vitamins. Such media formulations may prove valuable for studying the
biology and therapeutic responses of blood cancers in vitro.
Different tissues may provide metabolically distinct environments in the body, and
plasma-like media may not be suitable for the study of all cell types and cancers. Thus,
it may be useful to consider designing custom media on a case-by-case basis, so as to
best recapitulate the relevant tissue environment. This concept was exemplified by a
recent study that developed a cell culture medium that mimics the metabolic
environment of the brain, which can be used for studying neuronal biology in vitro (145).
However, it is important to note that the metabolic environments of tumors can differ
from that of blood and normal tissues (146). Thus, if it is possible to characterize a
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tumor environment of interest, then it may be useful to do in vitro studies of this cancer
type in a medium that metabolically mimics the native tumor environment.
In vivo nutrient environments, particularly those experienced by cancer cells in
orthotopic xenografts and autochthonous tumors, may be thought of as more
physiologically-relevant than that of cell culture systems. Importantly, there has been an
abundance of recent evidence demonstrating that manipulation of these nutrient
environments through diet can influence tumor growth (1, 5). In our work, we have
demonstrated that conventional mouse chow can lead to supra-physiological levels of a
vitamin in mouse plasma. Thus, it is possible that other in vivo cancer studies are
currently utilizing animal diets that cause non-physiological levels of metabolites to
circulate in blood, and as a result, through tumor microenvironments. Furthermore, we
showed that bringing the plasma level of thiamine down to normal human levels in mice
affected response of orthotopic leukemia xenografts to an established therapeutic. It
remains to be determined whether humanizing the plasma levels of other nutrients in
mouse cancer models could affect tumor growth or response to anti-cancer therapy, but
our results suggest such studies are warranted.
7.3 Further characterization of cancer nutrient dependencies is warranted
Recently, compounds have been designed for plasma depletion of amino acids other
than asparagine. These include an arginase, a cyst(e)inase, and a methioninase (147149). However, these compounds have only been tested on a subset of cancer models.
Custom diets have also been used to deplete certain amino acids in vivo, such as
serine and glycine (112). These dietary depletions have slowed tumor growth in some
cancer models, but also remain unstudied in many cancers. The techniques used in this
thesis, particularly barcode-based cell competition assays, can be used for a systematic
mapping of the responses of several cancers to various nutrient depletions. Although
we conducted some amino acid and vitamin deprivation studies in our work, it would be
interesting to see how barcoded libraries consisting of other cancer types may fare
under the conditions studied here or in other nutrient depletions. This would, at the very
least, pinpoint cancers that could be therapeutically targeted with recently described
compounds and dietary interventions.
Identifying cancers that are resistant and sensitive to particular nutrient depletions can
also lead us towards pinpointing biological pathways that are essential for maintaining
intracellular nutrient levels in specific cancer subtypes. This can lead to additional
translational findings, such as alternative ways to target cancers with a particular
nutrient dependency besides simply limiting dietary intake of the nutrient or depleting it
from plasma with an enzyme. For instance, mapping cell line responses to cholesterol
limitation identified a subset of cancers that cannot synthesize cholesterol and depend
on its uptake from the environment for proliferation (125). Thus, the LDLR gene required
for cholesterol uptake was found to be a potential therapeutic target in this subset of
cancers.
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In this work, we investigated the responses of several barcoded cancer cell lines,
primarily of blood and lymphoid origin, to depletion of non-essential amino acids and
vitamins. However, further work is needed to validate whether some of the cancer
subsets in our assays may be targetable with a nutrient-depleting drug or dietary
intervention. It will also be interesting to investigate the genetic determinants of growth
under the nutrient limitations that we have not yet followed up. In particular, future work
on vitamin depletions is warranted, as vitamins are relatively understudied in the cancer
metabolism field. Further work could determine whether subsets of cancers that
proliferate less under particular vitamin limitations may have targetable vitamin
utilization deficiencies, as exemplified by SLC19A2-low cells being targetable with
ASNase under physiological thiamine concentrations.
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CHAPTER 8. Materials and Methods

8.1 Experimental design
This study was designed to investigate the metabolic determinants of leukemia cell
response to ASNase treatment. To address this objective, we (i) performed unbiased
genetic screens to find genes that are essential for proliferation under ASNase
treatment, (ii) used loss-of-function studies and metabolite profiling to validate that
TPK1 enables ASNase resistance by producing the cofactor TPP, which allows
asparagine synthesis in glutamine-anaplerotic leukemia cells, (iii) used a DNA-barcoded
cell line competition assay, a genetic screen, and gain- and loss-of-function studies to
identify that physiological thiamine is limiting for ASNase response of a subset of
leukemia cell lines with low expression of the thiamine transporter SLC19A2, and (iv)
orthotopically engrafted leukemia cells with endogenously-low SLC19A2 in NSG mice to
show that dietary thiamine can influence ASNase sensitivity in leukemia.
8.2 Compounds, Cell lines, Cell Culture, and Constructs
Antibodies to GAPDH (GTX627408) were from GeneTex, and to TPK1 from Proteintech
(10942-1-AP). Conjugated Donkey Anti-Mouse IR-Dye 680LT and Donkey Anti-Rabbit
IR-Dye 800CW were from LI-COR Biosciences.
Asparagine, TPP, polybrene, and puromycin were from Sigma; blasticidin from
Invivogen; D-glucose from VWR; L-glutamine from Gibco; thiamine hydrochloride from
MP Biomedicals; E. coli L-asparaginase from BioVendor.
For glutamine tracing, a powder base media of RPMI without amino acids (R9010-01,
US Biological) was supplemented with all individual amino acids (except for asparagine
and glutamine) and glucose at RPMI concentrations. [U-13C]-glutamine (CLM-1822-H,
Cambridge Isotope Laboratories(CIL)) was used for tracing, and asparagine was
present or absent at RPMI concentration as detailed in experiment discussion. For
thiamine uptake experiments, Thiamine-(4-methyl-13C-thiazol-5-yl-13C3) hydrochloride
(“13C-thiamine”, 731188, Sigma) was added to cells in Hank’s Balanced Salt Solution
containing calcium chloride and magnesium chloride (“HBSS”, 24020-117, Gibco). In
tracing, uptake, and plasma profiling experiments, extraction solvents contained 15N and
13
C fully-labeled internal amino acid standards (MSK-A2-1.2, CIL) for normalization.
All human cell lines used were originally purchased from ATCC or DSMZ, or obtained
from the Sabatini and Weinberg labs (Whitehead Institute). Cell lines were verified to be
free of mycoplasma, and authenticated by STR profiling. Cell lines were typically
maintained in “standard RPMI”: RPMI-1640 medium containing 2 mM glutamine
(Gibco), 10% fetal bovine serum (“FBS”, Sigma), and penicillin-streptomycin (Gibco), at
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37 C and 5% CO2, unless otherwise noted. For all experiments, cells were counted with
a Beckman Z2 Coulter Counter.
The DNA-barcoded cell line competition assay and CRISPR-based screen done in low
thiamine media used thiamine-free RPMIs supplemented with 10% dialyzed FBS
(“dialyzed FBS”, 26400044, Gibco). All thiamine-free RPMIs were made with
glucose and glutamine at standard RPMI concentrations (11 and 2 mM,
respectively). For the competition assay, a powder base media of RPMI without
vitamins (US Biological) was supplemented with all individual vitamins (except for
thiamine) at RPMI concentrations. The CRISPR screen used a different powder base
media of RPMI made without thiamine (R9011-01, US Biological), which was used for
all other experiments that utilized thiamine-free RPMI.
For manipulating thiamine levels in the REH EV and SLC19A2 OE experiments,
thiamine-free RPMI was combined with 10% non-dialyzed FBS. For achieving
nanomolar thiamine levels that approximated physiological thiamine, thiaminefree RPMI was combined with 10% “double-dialyzed FBS”, obtained by further inhouse dialysis of Gibco’s dialyzed FBS. In-house dialysis was performed at 4 C
against a 20X volume of PBS, using regenerated cellulose dialysis tubing (21152-9, Fisherbrand), with a PBS change done after at least 8 hours of stirring,
such that 4 total PBS volumes were spent.
Lentiviral sgTPK1 vector was generated via ligation of hybridized oligos (below) into
lentiCRISPR-v2-puro, and lentiviral sgSLC19A2 vector was generated similarly (oligos
below) but using lentiCRISPR-v1-RFP. Both of these vectors were linearized with
BsmBI (New England BioLabs), and non-linearized vectors were used for Vector
Controls. sgRNA-resistant TPK1, or SLC19A2, cDNA gene blocks were cloned into
pMXs-IRES-blast by Gibson assembly, and uncut vector used as Vector Control.
Guide 5 in CRISPR/Cas9 screen, used to generate clonal KO1 and KO2 in proliferation
assays:
sgTPK1_5F, 5’-caccGGTGATATCATATAAGCGGT-3’;
sgTPK1_5R, 5’-aaacACCGCTTATATGATATCACC-3’.
Guide 3 in CRISPR/Cas9 screen, referred to as sgSLC19A2_1 in proliferation assays:
sgSLC19A2_3F, 5’-caccGAGGCTGGCGAAGAAGCCGT-3’;
sgSLC19A2_3R, 5’-aaacACGGCTTCTTCGCCAGCCTC-3’.
Guide 4 in CRISPR/Cas9 screen, referred to as sgSLC19A2_2 in proliferation assays:
sgSLC19A2_4F, 5’-caccGGACAAGAACCTGACCGAGA-3’;
sgSLC19A2_4R, 5’-aaacTCTCGGTCAGGTTCTTGTCC-3’.
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8.3 Generation of Knockout and cDNA Overexpression Cell Lines
Lentiviral sgTPK1 and sgSLC19A2 vectors generated as described above were
transfected into HEK293T cells with lentiviral packaging vectors VSV-G and Delta-VPR.
For the overexpression of TPK1 or SLC19A2, retroviral vector with cDNA generated as
above was transfected into HEK293T cells with retroviral packaging vectors Gag-pol
and VSV-G. X-tremeGENE reagent (Roche) was used for transfection. After 24 h, cells
were given fresh media. 48 hours after transfection, virus-containing media
supernatants were filtered through a 0.45 µm filter to eliminate cells. Cells to be
transduced were plated in 6-well tissue culture plates with appropriate virus and 8
mg/ml of polybrene. Cells were then spin-infected by plate centrifugation at 1,100 g for
1.5 h at 32 C. After 24 h, cells were given fresh media. At least 48 h after infection,
transduced cells were selected with puromycin, blasticidin, or by bulk-sorting on a BD
FACSAria (same gating for all samples, resulting in top 3-6% of RFP+ cells). Clonal
TPK1-knockout cells were generated from a single cell isolated by serial dilution of
transduced cells into a 96-well plate, in 0.2 mL of 100 µM TPP-supplemented standard
RPMI. Single cell clones were grown for ~3 weeks, and the resultant clones were
evaluated for TPK1 knockout by immunoblotting. TPK1 KOs were then maintained in
standard RPMI containing 20 nM TPP, as were the relevant Vector Control and cDNAadd-back controls, for at least 1 week prior to proliferation assays. Mixed population
cells transduced with sgSLC19A2s or Vector Control were maintained in standard
RPMI, as this already over-supplements thiamine at 3 µM. Of note, REH and Jurkat
cells expressing a luciferase reporter construct were used for generating the Vector- or
SLC19A2-overexpression pair, and the Vector-, sgSLC19A2_1-, or sgSLC19A2_2expressing lines, respectively.
8.4 Immunoblotting
Cells were first collected by centrifugation at 300 g for 4 min, and washed twice with
PBS. For blotting TPK1, cells were then lysed in cold RIPA buffer (20 mM Tris-Cl pH
7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% sodium
deoxycholate) supplemented with protease inhibitors (Roche), for 5 min on ice.
Supernatants were then collected by centrifugation at 20,000 g for 8 min at 4 C, and
protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo
Scientific) with a bovine serum albumin protein standard series. Samples were resolved
on 12% SDS-PAGE gels and analyzed by immunoblotting using antibodies listed above,
and a LI-COR Odyssey CLx Imaging System coupled with Image Studio Lite.
8.5 RNA Extraction, Reverse Transcription, and Real-time Quantitative PCR
RNA was extracted using the QIAGEN RNeasy mini kit, and 1 µg of RNA was reverse
transcribed using the Superscript III Reverse Transcriptase kit (Invitrogen), both
according to the manufacturer’s instructions. Real-time quantitative PCR (qPCR) was
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performed using SYBR Green PCR Master Mix (Applied Biosystems) and GAPDH was
used as a housekeeping control. qPCR primer sequences were as follows:
GAPDH forward, 5’-TTGGTATCGTGGAAGGACTC-3’
GAPDH reverse, 5’-ACAGTCTTCTGGGTGGCAGT-3’
SLC19A2 forward, 5’-GGCCGGACAAGAACCTGAC-3’
SLC19A2 reverse, 5’-ACACAGGAAACAGTAGCACCA-3’
8.6 Proliferation Assays
Cells were plated in 96-well plates at 1,000 cells per well in triplicate in a final volume of
0.2 ml in indicated medias and treatments. After 5-9 days of growth (depending on
proliferation rate), 40 µl of CellTiter-Glo reagent (Promega) was added and
luminescence was read on a SpectraMax M3 plate reader (Molecular Devices). For
each experiment, cells were also plated in triplicate in untreated media for an initial
luminescence time point for normalization. For each well, fold change in luminescence
was calculated and reported on a log2 scale. In all proliferation assays, we used an
ASNase dose ≤ 0.001 U/mL, which is a dose previously shown to deplete asparagine in
medium within 24 h, without affecting glutamine levels (150). In assays that required
achieving low thiamine levels, cells were first pre-incubated for 5-9 days in the same low
thiamine base media that was subsequently used for plating proliferation assays.
Proliferation assays were plated multiple times within this pre-incubation period with
similarly reproduced results.
8.7 Mouse studies
Animal studies were conducted according to a protocol approved by the Institutional
Animal Care and Use Committee (IACUC) at the Rockefeller University. All experiments
used age- and gender-matched NSG mice that were maintained on a standard lightdark cycle, with food and water provided ad libitum. Subcutaneous xenograft tumors for
DNA-barcoded competition assays were initiated by injecting 1.5 million of the pooled
cells in 100 µl of DMEM (Gibco) with 30% Matrigel (Corning), once on each mouse
flank. These mice were fed 5B1Q (TestDiet), a chow-based diet. Leukemia xenografts
were initiated by injecting 750,000 REH cells in 100 µl PBS through the tail vein. 2
weeks prior to tail-vein injections, these mice were switched from 5B1Q to a purified diet
of thiamine-deficient AIN-93G pellets (Dyets, Inc.) coupled with high or low thiamine
supplementation in water as described below. 1 week prior to tail-veins, REH cells were
switched from standard RPMI to a low thiamine media (thiamine-free RPMI + dialyzed
FBS) to remove excess thiamine from cells. To determine survival after leukemia
engraftment, weights were first checked weekly. After the first signs of progressive
disease, mice were monitored daily for deaths or signs of endpoint, and weights taken
at a minimum of twice weekly. Humane endpoints were 1) 20% weight loss from initial
weight, and 2) other obvious signs of disease such as hind limb dysfunction or
significant distress.

57

Low Thiamine groups were maintained by combining thiamine-deficient AIN-93G pellets
with water bottles containing 5 µM thiamine. High Thiamine groups were maintained by
combining the same thiamine-deficient pellets with 125 µM thiamine in water. Mice were
treated with L-asparaginase (1000 U/kg) daily for cell competition assays (2 weeks),
and twice weekly for leukemia xenograft experiments (~4 weeks). For all plasma
profiling, whole blood was collected using EDTA-coated capillaries or tubes by tail clip
(except for the 39d Low Thiamine time-point and the Chow vs High Thiamine data of
Figure 5.2, for which submandibular bleeds were done), then centrifuged at 20,000 g for
5 min at 4 C to yield the plasma supernatants used for LC-MS analysis.
8.8 Metabolite Profiling: Isotope Tracing, Isotope Uptake, Plasma Profiling
For glutamine tracing, the 3 cell types were first taken from their maintenance media (20
nM TPP), and washed twice with PBS. Cells were then plated at 500,000 cells/ml in
media containing 2.5 nM TPP, for ~1 day, to begin TPP depletion. To begin the
experiment, cells were washed again then plated in triplicate per condition in 6-well
plates at 1 million cells/ml, in a custom RPMI (described above) containing no
asparagine, no TPP, and 2 mM [U-13C]-glutamine (supplemented with 10% dialyzed
FBS). TPP (at RPMI thiamine concentration) and asparagine (at RPMI concentration)
were then added to wells as appropriate. After 24 h, 1 million cells from each well were
washed twice with 1 ml of cold 0.9% NaCl; a separate tube of 1 M cells was also
processed for each experimental condition to check protein content. After washing,
polar metabolites were extracted in 1 ml of cold 80% methanol containing internal amino
acid standards, by vortexing for 10 min at 4 C. Samples were then centrifuged at 20,000
g for 15 min at 4 C, and 900 µl of supernatants stored overnight at -80 C, then nitrogendried. Dried extracts were kept at -80 C until liquid chromatography / mass spectrometry
(“LC/MS”) analysis. Dried samples were resuspended in 100 µl 50:50 acetonitrile:water
and 2 µl was injected onto the LC/MS column. For protein quantification, NaCl-washed
cell pellets were instead stored at -20 C until RIPA lysis and protein quantification (as
described above for TPK1 immunoblotting).
For thiamine uptake experiments, the 3 cell types were first taken from their
maintenance in standard RPMI and washed twice with PBS. 4 million cells were then
plated in triplicate per condition in 6-well plates at 1 million cells/ml in warm HBSS. 13Cthiamine was then added to wells at a final concentration of 25 nM, for 5 min
incubations at 37 C. The assay was stopped by pipetting each well into an ice-cold tube
of HBSS containing unlabeled thiamine that came to 3 µM in the final mixture. Cells
were then washed twice with cold 0.9% NaCl and processed as described above for
polar metabolite extraction and LC/MS analysis. Dried samples were resuspended in 60
µl 50:50 acetonitrile:water, and 5 µl was injected onto the LC/MS column.
For plasma profiling, polar metabolites were extracted by combining plasma with cold
75:25 acetonitrile:methanol containing internal amino acid standards. 5 µl plasma was
combined with either 45 µl solvent for the in vivo competition assay data, or with 20 µl
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solvent for custom thiamine diet experiments (for quantifying low abundance thiamine in
plasma). This was followed by vortexing for 5 min at 4 C, then centrifuging at 20,000 g
for 10 min at 4 C. Supernatants were taken immediately for LC/MS analysis, or first
stored at -80 C for no longer than 24 h (samples were never dried). 2 µl (for competition
assay) or 5 µl (for custom thiamine diet experiments) were injected directly onto the
LC/MS column.
LC/MS analysis was conducted on a Q Exactive benchtop orbitrap mass spectrometer
equipped with an Ion Max source and a HESI II probe, which was coupled to a
Vanquish UPLC system (Thermo Fisher Scientific). External mass calibration was
performed using the standard calibration mixture every 4-6 days. Samples were injected
onto a ZIC-pHILIC 150 × 2.1 mm (5 µm particle size) column (EMD Millipore).
Chromatographic separation was achieved using the following conditions: buffer A was
20 mM ammonium carbonate, 0.1% ammonium hydroxide; buffer B was acetonitrile.
The pH for buffer was adjusted to 9.3 using formic acid. The column oven and
autosampler tray were held at 25 C and 4 C, respectively. The chromatographic
gradient was run at a flow rate of 0.150 ml min−1 as follows: 0–22 min: gradient from
90% to 40% B; 22-24 min: held at 40% B; 24–24.1 min: return to 90% B; 24.1–30 min:
hold at 90% B. The mass spectrometer was operated in full-scan, polarity switching
mode with the spray voltage set to 3.0 kV, the heated capillary held at 275 C, and the
HESI probe held at 250 C. The sheath gas flow was set to 40 units, the auxiliary gas
flow was set to 15 units. The MS data acquisition was performed in a range of 55–825
m/z, with the resolution set at 70,000, the AGC target at 10 × 106, and the maximum
injection time at 80 msec. Relative quantitation of polar metabolites was performed with
Skyline Daily from MacCoss Lab Software (151), using a 2 ppm mass tolerance. For all
experiments, total signal for a metabolite was first quantified in Skyline, in which
metabolite identification was based on mass, retention time, and the signal observed for
an in-house chemical standard of the metabolite. The chemical standard was present in
a separate injection of the same LC/MS run. For glutamine tracing data, natural
abundance corrections were not performed in Skyline, as the primary mass
isotopologues of interest were M+4 and M+5 species, which were deemed to have
negligible natural abundance for the metabolites analyzed. For instance, naturallyoccurring asparagine is ~0.001% M+4 asparagine and naturally-occurring glutamate is
~0.0001% M+5 glutamate. For normalization, raw signal of each metabolite was first
normalized to the appropriate labeled internal AA standard in that injection (except for
the thiamine uptake data, where raw signal is presented because no signal was
detected in sgSLC19A2 samples). Metabolite levels were also normalized by cell
counting (per well) and BCA protein quantification (per condition) for glutamine tracing,
by cell counting for thiamine uptake, and by plasma/serum volume as appropriate.
8.9 CRISPR/Cas9-based genetic screens
The metabolism-focused sgRNA library preparation, and details on performing screens,
were previously described (152-154). sgRNA oligonucleotides were synthesized by
59

Agilent and amplified by PCR. After Illumina deep sequencing of initial and final screen
pools, a guide score for each screen flask was defined as the log2 fold change of
sgRNA abundance from initial to final. Gene scores for each flask were defined as the
median of the guide scores corresponding to a gene, and the complete lists of gene
scores were used to make the gene score vs. gene score linearity plots presented. For
each sgRNA of a gene, the guide score for the control flask was subtracted from the
guide score for the experimental flask, and the median of the resulting values was
defined as the differential gene score. A gene lethality cut-off was used for differential
gene score analysis: genes that had a gene score less than or equal to -1 in the
appropriate control condition were removed from the gene score list, and the updated
gene list was ranked by differential gene score of experimental vs. control to give the
differential gene score graphs presented. Full screen results are available as
supplementary data.
8.10 DNA-barcoded cell line competition assays
DNA-barcoded cell lines were generated, and competition assays performed, as
previously described (3, 125). In brief, three unique 7-bp sequences were transduced
into each cancer cell line using lentiviruses generated with pLKO.1-puro vector, such
that each cell line had 3 data-points used for statistical analysis. To perform cell
competition assays, barcoded cell lines were mixed in approximately equal amounts, an
initial pool sample was taken, and the remainder of the pool was grown for ~2 weeks
under indicated in vitro or in vivo conditions. At endpoint, genomic DNA was extracted
from the initial and final pool samples, DNA barcode regions were amplified by PCR,
and PCR amplicons were processed for Illumina deep sequencing. Fold-change of
barcode abundance from initial to final pools was determined, and results presented as
detailed in appropriate figures.
8.11 Patient tumor and cell line RNA sequencing
Patient RNAseq data for SLC19A2, SLC19A3, TPK1, and ASNS were generated by the
Therapeutically Applicable Research to Generate Effective Treatments
(https://ocg.cancer.gov/programs/target) initiative, phs000218. These data were part of
the Acute Lymphoblastic Leukemia (ALL) Expansion Phase 2 TARGET Sub-study,
phs000464, and were downloaded from the TARGET Data Matrix
(https://ocg.cancer.gov/programs/target/data-matrix) on December 10, 2019. All files
used were in the BCCA subdirectory and tumor sample details are indicated within the
relevant figures. Cancer cell line RNAseq data presented throughout this study were
obtained from the CCLE (https://portals.broadinstitute.org/ccle/data), accessed on
January 27, 2020 (file version: CCLE_RNAseq_rsem_genes_tpm_20180929.txt.gz)
(155).
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8.12 Statistical Analysis
Significance P values, sample sizes, and means are indicated in text or figures. Error
bars represent standard deviation from biological replicates or independent samples as
indicated. Statistical analyses were performed with GraphPad Prism or Microsoft Excel
as appropriate. P ≤ 0.05 was considered statistically significant, and the specific
statistical test used and any adjustments for multiple comparisons are indicated in the
relevant figure legends.
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